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ABSTRACT 
 
 
The goal of my dissertation work was to examine the systems biology of torsinA, 
a DYT1 dystonia-associated protein, by using rodent model systems.  TorsinA is a 
putative ATPase associated with a variety of cellular activities (AAA+).  Deletion of 
glutamic acid residue 302/303 in TOR1A is causally associated with many cases of early-
onset primary dystonia.   
 
In our work, transient forebrain ischemia and sciatic nerve transection were used 
as central and peripheral neural perturbations, respectively, to gain insight into the in vivo 
role(s) of torsinA.  Moreover, transgenic mouse models that overexpress either human 
mutant torsinA (hMT) or wild-type torsinA (hWT) were used to analyze the behavioral, 
morphological, neurochemical, and brain metabolical consequences of increased mutant 
torsinA burden.   
 
After transient forebrain ischemia and sciatic nerve transection, torsinA 
expression levels were temporally increased in both the central and peripheral nervous 
systems.  In the hippocampus and dorsal root ganglion, increased torsinA 
immunoreactivity was found located in neuronal populations such as projection neurons, 
interneurons, and ganglion cells, and in glial elements such as reactive astrocytes and 
satellite cells.  These results suggest that torsinA participates in the response of neural 
tissue to central and peripheral insults, and that limited recruitment of intact functional 
torsinA might contribute to the onset of DYT1 dystonia in TOR1A ΔGAG mutation 
carriers.  The striking induction of torsinA in astrocytes and satellite cells points to the 
potential involvement of glial elements in the pathobiology of DYT1 dystonia. 
 
In the DYT1 transgenic mice, mutant torsinA burden resulted in prolonged 
traversal times and more slips on a raised-beam task; widened hind-base width; increased 
dopamine turnover in the striatum, and a shift in brain energy demand from the basal 
ganglia to olivocerebellar pathways.  However, no morphological alterations were 
detected in the mutant mice with either light or electron microscopy.  Our neurochemical 
findings in DYT1 transgenic mice are compatible with previous postmortem 
neurochemical studies of human DYT1 dystonia.  Increased striatal dopamine turnover in 
torsinA mutant mice suggests that the nigrostriatal pathway may be a site of functional 
neuropathology in DYT1 dystonia.  The relatively attenuated energy demand in basal 
ganglion output regions may be a manifestation of a primary functional abnormality in 
the nigrostriatal system of DYT1 mutation carriers and the relatively elevated energy 
demand in cerebellar cortex might be a compensatory response to dysfunction of the 
basal ganglia.  
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CHAPTER 1. INTRODUCTION 
 
 
1.1 DYSTONIA 
  
Dystonia has been defined by the Scientific Advisory Board of Dystonia Medical 
Research Foundation as a syndrome of sustained involuntary muscle contractions; it 
frequently causes twisting and repetitive movements, or abnormal movements and 
postures (1988).  It is generally accepted that dystonia is caused by a dysfunction of the 
central nervous system with a resultant failure to “relax” muscles that are not required for 
a particular motor act; that failure results in simultaneous contraction of opposing 
muscles.  Dystonia tends to improve with relaxation, sleep, or sensory tricks, and 
intensify with action.  Dystonia does not discriminate, and affects humankind of all ages, 
both genders, and racial backgrounds.  Dystonia affects over 300,000 people in North 
America, and is the third most-common movement disorder after Parkinson’s disease and 
tremor in the United States (Dystonia Medical Research Foundation).   
 
Dystonia is a syndrome associated with a heterogeneous collection of genes and 
disorders.  Dystonia may be idiopathic (i.e., primary) or secondary to acquired insults to 
the CNS and PNS such as trauma, metabolic disorders, and stroke.  Dystonia may also be 
associated with other neurological disorders such as Huntington's disease, Parkinson's 
disease, Lesch–Nyhan syndrome, and ataxia telangiectasia.  Primary dystonia can be 
classified by age of onset as early- or late-onset dystonia, and by topographic distribution 
as focal, segmental, multifocal, and generalized (Nemeth, 2002; Tarsy and Simon, 2006).   
 
The severity of the dystonic symptoms may show a modest variability during the 
course of each day.  Dystonia may be associated with pain, functional disability, and a 
significantly impaired quality of life.  In general, the primary dystonias are not associated 
with intellectual impairment or shortened lifespan.  At present, there are no permanent 
cures for dystonia.  However, a variety of treatments is available to improve the 
symptoms.  Treatment options include dopamine-depleting agents such as tetrabenazine, 
anticholinergics, benzodiazepines, botulinum toxin injections, deep-brain stimulation, 
and physical therapy (Klein and Ozelius, 2002; Tarsy and Simon, 2006).  
 
 
1.1.1 Classification 
 
The heterogeneity of dystonia has prompted the development of several 
classification schemes.  Classically, dystonia can be clinically classified in three ways: by 
the age of symptom onset as early-onset and adult-onset; by topographic distribution as 
focal, segmental, multifocal, generalized, and hemidystonia; and etiologically as primary, 
dystonia-plus, heredodegenerative, and secondary; and genetically according to the 
monogenic gene mutation (Fahn et al., 1998; de Carvalho Aguiar and Ozelius, 2002; 
Tarsy and Simon, 2006).   
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Based on data from patients with primary torsion dystonia (Bressman et al., 1998; 
2000), if symptoms begin before the age of 26, dystonia is classified as early-onset 
dystonia, whereas, if symptoms begin after 26 years of age, dystonia is classified as late-
onset dystonia.  The age of onset is very important for prognosis and counseling.  Early-
onset dystonia can be rapidly progressive,; it often begins in a leg and commonly spreads 
to involve other parts of the body.  In contrast, late-onset dystonia often remains focally-
distributed.   
 
Dystonia can also be classified following the topographic distribution of the 
affected region.  The term “focal” is applied when only a single body part is affected.  
More specific terms are also used to describe focal dystonias which affect a single body 
part, such as blepharospasm (eyes), cervical dystonia (neck, also called torticollis), or 
laryngeal dystonia (larynx, also called spasmodic dysphonia).  When two or more 
contiguous body parts are involved, it is called segmental dystonia; for example, cranial–
cervical dystonia, crural dystonia, or brachial dystonia.  In multifocal dystonia, two or 
more noncontiguous body parts are involved.  Generalized dystonia refers to dystonia, 
which involves the legs, or one leg and the trunk, in addition to one other area of the 
body.  The term “hemidystonia” is used to denote involvement of the arm and leg on the 
same side of the body.   
 
Etiologically, dystonia is classified as primary, dystonia-plus, heredodegenerative 
and secondary.  Primary dystonia includes syndromes in which dystonia is the sole 
phenotypic manifestation with the exception that tremor can be present as well.  The 
“dystonia-plus” category includes syndromes with other neurological manifestations in 
which no evidence of neurodegeneration has been identified, such as dopa-responsive 
dystonia, and myoclonus-dystonia. Heredodegenerative dystonia includes syndromes in 
which dystonia occurs in the setting of neurodegenerative diseases such as Parkinson’s 
disease, multiple system atrophy, and Huntington’s disease.  Secondary dystonia includes 
syndromes in which dystonia is the manifestation of a structural or metabolic abnormality 
of the brain or peripheral nervous system.  Secondary dystonia can be associated with 
strokes, brain tumors, neurotoxins, infectious (e.g., human immunodeficiency virus), and 
demyelinating disorders (e.g., multiple sclerosis, and neoplasic diseases). 
 
 
1.1.2 Genetics and Dystonia 
 
Over 16 forms of hereditary dystonia (DYT1-16; Table 1-1) have been described 
to date (Klein and Ozelius, 2002; Nemeth, 2002; Breakefield et al., 2008).  Within those 
16 hereditary disorders included in the DYT classification scheme, only DYT1, DYT2, 
DYT4, DYT6, DYT7, and DYT13 are genuine subtypes of primary dystonia.  DYT1, 
DYT2, DYT4, and DYT6 often begin focally prior to generalization.  However, DYT7 
and DYT13 typically persist as focal dystonias.  DYT5, DYT11, DYT12, DYT14, 
DYT15, and DYT16 belong to dystonia-plus family, because additional neurological 
features are present in addition to dystonia.  For example, DYT5, DYT12, and DYT16  
frequently exhibit Parkinsonism, and DYT11 and DYT15 often present with myoclonus.   
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Table 1-1.  Molecular classification of dystonia. 
 
Locus Designation OMIM Chromosomal location Gene 
Mode of 
inheritance Clinical characteristics Reference 
DYT1 
 
 
Dystonia 1; early-onset primary 
dystonia; Oppenheim's dystonia 
128100 9q32-34 TorsinA (TOR1A) AD, incomplete 
penetrance 
Early-onset generalized, usually starts in a 
limb 
Ozelius et al., 
1997 
DYT2 
 
Dystonia 2; autosomal recessive 224500 Unknown Unknown AR Early-onset, generalized or segmental  Zlotogora, 2004 
DYT3 Dystonia 3; X-linked dystonia-
parkinsonism; ‘lubag’ 
314250 Xq13.1 TATA-binding 
protein-associated 
factor-1 (TAF1) 
XR Only discriped in individuals from 
Philipines; usually male; Segmental or 
generalized dystonia with parkinsonism 
unresponsive to L-dopa; progressive 
neurodegenerative syndrome 
 
Makino et al., 
2007 
DYT4 
  
 
Dystonia 4; “non-DYT1” 128101 Unknown Unknown AD Single large Australian family; laryngeal 
and cervical dystonia 
Ahmad et al., 
1993 
DYT5 
GCH1 
Dystonia 5; dopa-responsive 
dystonia-parkinsonism 
128230 14q22.1- 
q22.2 
GTP 
cyclohydrolase I 
(GCH1) 
 
AD, incomplete 
penetrance 
Dystonia with concurrent or subsequent 
parkinsonism, diurnal worsening of 
symptoms and a dramatic response to L-
dopa 
 
Ichinose et al., 
1994 
DYT5 
TH 
 
Segawa syndrome 191290 11p15.5 Tyrosine 
hydroxylase 
AR Same as DYT5/GCH1 Ludecke et al., 
1995 
DYT6 
 
Dystonia 6; adolescent-onset of 
mixed type 
602629 8p21-q22 Unknown AD Adolescent-onset, mostly segmental PTD, 
rarely generalizes 
 
Almasy et al., 
1997 
DYT7 
 
Dystonia 7; adult-onset focal 602124 18p11.3 Unknown AD, incomplete 
penetrance 
Adult-onset focal dystonia (torticollis, 
writer’s cramp, dysphonia, or 
blepharospasm) 
 
Leube et al., 
1996 
DYT8 Dystonia 8; paroxysmal dystonic 
choreoathetosis; paroxysmal 
non-kinesigenic dyskinesia 
 
118800 2q35 Myofibrillogenesis 
regulator-1 (M 
R1) 
AD, incomplete 
penetrance 
Attacks of dystonia/choreoathetosis, 
precipitated by stress, fatigue, alcohol, and 
chocolate 
Rainier et al., 
2004; 
Djarmati et al., 
2005 
DYT9 Dystonia 9; paroxysmal 
choreoathetosis with episodic 
ataxia and spasticity 
601042 1p21-p13.3 Unknown AD Attacks of dystonia, parasthesias, double 
vision, precipitated by exercise, stress, and 
alcohol; spastic paraplegia between attacks 
 
Auburger et al., 
1996 
DYT10 Dystonia 10; paroxysmal 
kinesigenic choreoathetosis 
128200 16p11.2-q12.1 Unknown AD, incomplete 
penetrance 
Attacks of dystonia/choreoathetosis, 
brought on by sudden movements; respond 
to anticonvulsant therapy 
Tomita et al., 
1999 
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Table 1-1.  (Continued). 
 
Locus Designation OMIM Chromosomal location Gene 
Mode of 
inheritance Clinical characteristics Reference 
DYT11 Dystonia 11; myoclonus-
dystonia 
159900 7q21 
11q23 
Epsilon-
sarcoglycan 
(SGCE) 
 
AD, incomplete 
penetrance 
Rapid, jerk-like movements, responsive to 
alcohol; combined with variable degrees of 
dystonia 
Zimprich et al., 
2001 
DYT12 Dystonia 12; rapid-onset 
dystonia-parkinsonism 
128235 19q12-q13.2 Alpha-3 subunit of 
the N,K-ATPase 
(ATP1A3) 
AD, incomplete 
penetrance 
Dystonia or parkinsonism developing over 
hours or weeks 
Kramer et al., 
1999; 
de Carvalho 
Aguiar et al., 
2004 
DYT13 Dystonia 13; 
multifocal/segmental dystonia 
607671 1p36.32-
p36.13 
Unknown AD, incomplete 
penetrance 
Focal or segmental dystonia with onset 
either in the cranial-cervical region or in 
the upper limbs; mild course 
 
Valente et al., 
2001 
DYT15 Dystonia 15; alcohol-responsive 
myoclonic dystonia 
607488 18p11 Unknown AD, incomplete 
penetrance 
Alcohol-responsive myoclonic dystonia 
characterized mainly by jerky movements 
of the upper limbs, hands, and axial 
muscles 
 
Grimes et al., 
2002 
DYT16 Dystonia 16; young-onset 
dystonia-parkinsonism 
612067 2q31.3 Protein kinase, 
interferon-
inducible double-
stranded RNA-
dependent 
activator 
(PRKRA) 
AR Progressive, generalised, early-onset 
dystonia with axial muscle involvement, 
oromandibular (sardonic smile), laryngeal 
dystonia and, in some cases, parkinsonian 
features, and do not respond to levodopa 
therapy 
Camargos et al., 
2008 
 
Notes: AD, autosomal dominant; AR, autosomal recessive; PTD, primary torsion dystonia; XR, X-linked recessive. 
Modified with permission.  Klein C, Ozelius LJ (2002) Dystonia: clinical features, genetics, and treatment. Curr Opin Neurol 
15(4): 491-497.
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DYT3 is classified as a heredodegenerative dystonia, because post-mortem histological 
analysis has shown neuronal loss and astrocytosis in the striatum.  DYT8, DYT9, and 
DYT10 are paroxysmal dystonias that are triggered by stress, drugs, exercise, or sudden 
movements.  
 
Most of the hereditary dystonias are inherited in the autosomal dominant (AD) 
mode with incomplete penetrance.  The low penetrance of many of the hereditary 
dystonias suggests that other genetic traits or environment factors might play a role in 
their onset.   
 
To date, eight genes, mutations of which are responsible for the onset of inherited 
form of dystonia, have been identified: (1) DYT1 (Oppenheim's dystonia, OMIM 
128100) due to mutation in TOR1A that encodes torsinA (Ozelius et al., 1997); (2) DYT3 
(Lubag, OMIM 314250) due to insertion mutations in TATA-binding protein-associated 
factor 1 (TAF1) located on chromosome Xq13.1 (Makino et al., 2007); (3) DYT5 (dopa-
responsive dystonia, OMIM 128230) autosomal dominant form caused by mutations in 
the gene for guanosine triphosphate cyclohydrolase I (GCH1)(Nygaard et al., 1993; 
Ichinose et al., 1994), (4) autosomal recessive form caused by a mutation in tyrosine 
hydroxylase (TH)(Lüdecke et al., 1995); (5) DYT8 (paroxysmal non-kinesigenic 
dyskinesia, OMIM 118800) secondary to missense mutations in the myofibrillogenesis 
regulator 1 (MR-1)(Rainier et al., 2004; Djarmati et al., 2005); (6) DYT11 (myoclonus-
dystonia syndrome, OMIM 159900) secondary to mutations that lead to a truncation of 
the membrane glycoprotein ε-sarcoglycan (SGCE)(Zimprich et al., 2001); (7) DYT12 
(rapid-onset dystonia-parkinsonism, OMIM 128235) caused by mutations in the gene that 
encodes the α-3 subunit of the Na+/K+ ATPase (ATP1A3)(de Carvalho Aguiar et al., 
2004); and (8) DYT16 (young-onset dystonia-parkinsonism, OMIM 612067) due to a 
mutation in the stress-response gene PRKRA, which encodes the protein kinase, 
interferon-inducible double-stranded RNA-dependent activator (Camargos et al., 2008). 
 
 
1.2 DYT1 DYSTONIA 
 
Ozelius and colleagues (1997) identified gene TOR1A in chromosome 9q32-9q34.  
A 3-bp deletion (GAG) in Exon 5 of TOR1A is associated with the majority of the cases 
of early-onset primary generalized dystonia.  Some cases are clearly familial, whereas 
others appear sporadic.  TOR1A is expressed ubiquitously in human tissues, and encodes 
a protein named torsinA.  The GAG deletion mutation results in the loss of a glutamic 
acid in the carboxy terminus of torsinA (Ozelius et al., 1997; 1999).  DYT1 dystonia is an 
uncommon disorder.  The prevalence of the DYT1 GAG deletion has been reported to be 
0.3 to 0.5 per 100,000 in the general population of Europe.  However, in Ashkenazi Jews, 
the frequency is much higher, around 1 per 2,000 to 6,000 (Kamm, 2006).   
  
DYT1 dystonia is a severe hereditary form of early-onset primary generalized 
dystonia.  It is an autosomal dominant disease with less than 40% penetrance.  The onset 
of dystonia usually appears between 5 to 26 years of age.  Onset before 4 years or after 
28 years is rare.  Generally, the symptoms usually develop first in the legs as focal limb 
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dystonia, and typically generalize within 5 years (Bressman et al., 1998; 2000).  
However, variable phenotypic expressions have also been reported.  Grundmann and 
colleagues (2003) screened a moderately large cohort of German dystonia patients with a 
GAG deletion in TOR1A and evaluated the dystonic phenotypic expression in DYT1 
carriers, and found that 6 out of 256 patients were DYT1 haplotype carriers.  Two of the 
patients expressed the classic phenotype of early-onset primary generalized dystonia, two 
expressed multifocal dystonia, and the remaining two subjects presented with writer's 
cramp, and showed only slight progression over several years.  
  
The pathophysiology of DYT1 dystonia is not well understood.  Postmortem 
neuropathological studies of brains from subjects with primary dystonia failed to reveal 
any consistent evidence of neuronal loss, inflammation, or neurodegeneration.  These 
findings suggest that functional and/or ultrastructural abnormalities, rather than 
neurodegeneration, underlie dystonic symptoms (Rostasy et al., 2003).   
 
 
1.2.1 Neuropathology in DYT1 Dystonia 
 
Zweig (1988) have examined brain tissues from two cases of early-onset primary 
generalized dystonia.  They found neurofibrillary tangles in several brainstem nuclei such 
as locus ceruleus (LC), substantia nigra pars compacta (SNpc), pedunculopontine nucleus 
(PPN), and dorsal raphe (RMg) nucleus, and a mild neuronal loss within the LC in one 
case.  However, they did not reveal consistent findings in the other case.  Hornykiewicz 
and colleagues (1986) also reported that they did not find important histological changes 
in the basal ganglia, cerebral cortex, and some of the tested brainstem nuclei in two cases 
of early-onset primary generalized dystonia.  Rostasy and colleagues (2003) carefully 
examined striatum, cerebellum, hippocampal formation, and SN of post-mortem brain 
tissues from three manifesting DYT1 carriers, three non-DYT1 dystonic patients, and 
eleven controls.  They did not reveal any disease-specific evidence of gliosis and 
apoptosis.  They did not detect cytoplasmic inclusion bodies in neurons in all brain 
tissues tested from dystonia patients.  However, they noticed larger nigral dopaminergic 
neurons in all dystonia brains, and more closely spaced neurons in SN in manifesting 
DYT1 carriers.  McNaught and colleagues (2004) later reported evidence of perinuclear 
inclusion bodies in some of the neurons in PPN, the cuneiform nucleus and 
periaqueductal gray (PAG), but not in the SNpc, striatum, hippocampus, and neocortex in 
four manifesting DYT1 carriers tested.  These multifarious findings suggest that 
functional and/or ultrastructural abnormalities rather than neurodegeneration underlie 
DYT1 dystonia.   
 
 
1.2.2 Neurochemical Studies in DYT1 Dystonia 
 
Several groups have studied the neurochemical changes in DYT1 dystonia and 
have generated diverse findings.  Hornykiewicz and colleagues (1986) reported 
norepinephrine (NE) and serotonin (5-HT) level changes in several brain regions in two 
cases of early-onset primary generalized dystonia, with decreased dopamine (DA) levels 
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in striatum in one case.  Furukawa and colleagues (2000) noticed the attenuated striatal 
DA levels (50% to 54% of control means) in the rostral putamen and caudate nucleus in 
one case of DYT1 dystonia.  Augood and colleagues (2002) reported significantly 
increased striatal 3,4-dihydroxyphenylacetic acid (DOPAC)/DA, and a trend towards 
reduced striatal D1 and D2 receptor binding in three cases of DYT1 dystonia compared to 
three controls.  Asanuma and colleagues (2005) studied nine non-manifesting DYT1 
carriers and found that attenuated D2 receptor binding (85% of control) was a trait of the 
DYT1 genotype.  These various investigations indicate that imbalances in nigrostriatal 
neurochemical  signaling may contribute to disease manifestations in DTY1 dystonia.    
 
 
1.2.3 Neuroimaging Studies in DYT1 Dystonia  
  
Neuroimaging studies of DYT1 dystonia include metabolic and structural 
approaches.  In the metabolic studies, hyperactivity has been reported in several brain 
regions in DYT1 carriers.  Eidelberg and colleagues (1998) identified brain metabolic 
activity changes in DYT1 carriers with [18F] fluorodeoxyglucose (FDG) and positron 
emission tomography (PET).  Those changes include genotype-related hyperactivity in 
lentiform nuclei, cerebellum, and supplementary motor areas (SMA), and syndrome-
related hyperactivity in the midbrain, cerebellum, and thalamus.  Ghilardi and colleague 
(2003) reported brain functional abnormalities during task performance by using H215O 
PET.  They found an increased activation in the left premotor cortex and right SMA, and 
an attenuated activation in the posterior medial cerebellum in DYT1 carriers during 
motor performance as well as an increased activation in the left ventral prefrontal cortex 
and lateral cerebellum in DYT1 carriers during sequence learning.  Carbon and 
colleagues (2004a) reported syndrome-related hyperactivity in the presupplementary 
motor area (Brodmann area [BA] 6) and parietal association cortices bilaterally (BA 
40/7), and genotype-related hyperactivity in the putamen, anterior cingulate (BA 24/32), 
and cerebellar hemispheres in DYT1 carriers with [18F] FDG PET. 
 
In neurostructural studies, Carbon and colleagues (2004b; 2008a) noticed 
decreased fractional anisotropy (FA) in several brain regions in DYT1 carriers with 
diffusion tensor magnetic resonance imaging (DTI), that is a marker of axonal 
disintegrity.   Those decreased fractional anisotropy included syndrome-related decrease 
in the left dorsal pontine brainstem and in the white matter of the sensorimotor cortex 
bilaterally, and genotype-related decrease in the white matter of the sensorimotor cortex 
in DYT1 carriers.    
 
In aggregate, work to date in humans indicates DYT1 dystonia is due to 
functional and/or ultrastructural abnormalities of the brain rather than 
neurodegeneration..   
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1.3 TORSINA  
 
TorsinA is the protein encoded by TOR1A.  The dystonia-related GAG deletion 
results in the loss of a glutamic acid in the carboxy terminal (Ozelius et al., 1997; 1999).  
The molecular and cellular functions of torsinA are essential but not well understood.  
From the amino acid sequence, torsinA belongs to ATPases associated with a variety of 
cellular activities (AAA+) superfamily (Ozelius et al., 1997; 1999).  TorsinA possesses 
an N-terminal signal sequence, a single AAA+ module, and two biochemically-confirmed 
glycosylation sites (Figure 1-1).  The AAA+ module contains four conserved motifs: a 
Walker A motif that regulates nucleotide binding; a Walker B motif that is crucial for 
ATPase activity; a sensor 1 that is critical for nucleotide hydrolysis; and sensor 2 that is 
essential for nucleotide binding and hydrolysis(Ozelius et al., 1997; Neuwald et al., 1999; 
Ozelius et al., 1999; Joshi et al., 2003; Kamm et al., 2004; Hanson and Whiteheart, 2005; 
Callan et al., 2007).  Unlike the other three motifs, which are very conserved and play 
similar functions between AAA+ proteins, sensor 2 determines the specificity of the 
protein (Joshi et al., 2003).  Sensor 2 is also a very important domain to regulate subunit 
and/or substrate conformational changes.  It’s a function-determined domain for AAA+ 
proteins because AAA+ proteins assemble into hexamers to function, and the most 
essential function is to regulate conformational changes of the substrates (Neuwald et al., 
1999; Joshi et al., 2003; Hanson and Whiteheart, 2005).  Members of the AAA+ family 
function as molecular chaperones for protein quality control (protein complex assembly, 
operation, disassembly, protein folding, unfolding, and degradation), membrane fusion 
and vesicular transport, and cytoskeletal regulation (Neuwald et al., 1999; Vale, 2000; 
Ogura and Wilkinson, 2001), all of these activities might provide insight regarding the 
function of torsinA. 
 
TorsinA is an endoplasmic reticulum (ER)-resident glycoprotein (Hewett et al., 
2003; Kuner et al., 2003; Liu et al., 2003; Callan et al., 2007).  Strong torsinA-
immunoreactivity (IR) is located diffusely in the cytoplasm of neurons that extends 
throughout neurites to synapses (Konakova et al., 2001; Konakova and Pulst, 2001; 
Augood et al., 2003; Kuner et al., 2003; Kamm et al., 2004).  When overexpressed in 
cultured cells, mutant torsinA is enriched at the nuclear envelope (Goodchild and Dauer, 
2004; Naismith et al., 2004).   
 
In normal brain, torsinA-IR is widely distributed in all anatomical structures with 
intense IR detected in pyramidal neurons in neocortex, cholinergic interneurons in 
striatum, pyramidal neurons in hippocampus, motor neurons in the trigeminal nuclei, and 
dopaminergic neurons in the SNpc (Shashidharan et al., 2000a; Konakova and Pulst, 
2001; Xiao et al., 2004).  In rat brain, torsinA-IR is present in the cytoplasm, dendrites 
and axons but not in nuclei (Xiao et al., 2004).   
 
TorsinA might function as a chaperone for unfolded or degraded proteins, and 
might facilitate movement of polytopic proteins to the cell surface (Torres et al., 2004).  
TorsinA has been localized to protein aggregations such as Lewy bodies in Parkinson's 
disease brain and inclusion bodies in trinucleotide repeat diseases, and its overexpression
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Figure 1-1.  Alignment of human, rat, and mouse torsinA amino-acid sequences. 
Sequence disparities are shaded. The N-terminus of torsinA contains a 20-aa hydrophobic 
signal sequence (underlined) , a AAA+ module, two biochemically-confirmed 
glycosylation sites (N143, N158; solid triangle) and six conserved cysteine residues 
(C44, C49, C50, C162, C280, C319; asterisk).  The AAA+ module includes four 
conserved motifs (walkerA, walkerB, sensor1, sensor2; bold italic and underlined).  The 
site of GAG (E) deletion is presented bold and marked as solid circle.  The possible 
phosphorylation sites for protein kinase C (PKC) and casein kinase 2(CK2) are boxed. 
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facilitates the clearance of those protein aggregates (Shashidharan et al., 2000b; Sharma 
et al., 2001; McLean et al., 2002; Caldwell et al., 2003; Walker et al., 2003).  TorsinA 
was found to interact with kinesin light chain 1 (KLC1) in a yeast two-hybrid study 
(Kamm et al., 2004).  KLC1 is part of the heterotetrameric motor protein kinesin-I, and is 
thought to be involved in cargo binding and/or kinesin-I activity regulation (Kamal and 
Goldstein, 2002).  TorsinA was also shown to modulate the cellular trafficking of the 
dopamine transporter (Torres et al., 2004; Cao et al., 2005), as well as other membrane-
bound proteins, including G protein-coupled receptors, transporters, and ion channels 
(Torres et al., 2004).  In addition, overexpression of torsinA facilitates the clearance of 
another dystonia-related protein, SGCE, by the ubiquitin proteosome system, and protects 
PC12 cells against a variety of cellular insults, including serum deprivation and oxidative 
stress (Kuner et al., 2003; Shashidharan et al., 2004; Esapa et al., 2007).  Similarly, 
overexpression of torsinA protects dopamine neurons from oxidative stress in C. elegans 
(Cao et al., 2005).  In a mammalian model, torsinA expression was up-regulated after 
oxidative stress in dopamine neurons in vivo (Kuner et al., 2004). 
 
The chaperone function(s) of torsinA might include maintenance of cellular 
polarity and regulation of neurite extension by interactions with the cytoskeleton.  
Support for this hypothesis derives from several fronts.  First, in vitro research has shown 
that torsinA-IR was localized to filopodia in cultured cells, whereas torsinA-IR has been 
detected in synapses in brain tissues (Konakova et al., 2001; Konakova and Pulst, 2001; 
Augood et al., 2003; Kamm et al., 2004).  TorsinA was also confirmed to localize with 
microtubules and to co-immunoprecipitate with microtubule-associated protein tau 
(Ferrari-Toninelli et al., 2003; 2004; Hewett et al., 2006).  Next, overexpression of 
mutant torsinA inhibited neurite extension; however, attenuation of wild-type torsinA 
facilitated neurite extension in SH-SY5Y cells (Ferrari-Toninelli et al., 2004; Hewett et 
al., 2006).  TorsinA is critical for postnatal neurodevelopment.  The expression of torsinA 
is striking in the prenatal and early postnatal period, with a most intense expression in 
cerebellum and cholinergic interneurons in striatum at postnatal day 14 (Xiao et al., 
2004), which is a period of intense cellular migration, neurite extension, and 
synaptogenesis.  TorsinA knock-out and homozygous ΔGAG knock-in mice die shortly 
after birth (Goodchild et al., 2005). In aggregate, these studies suggest that torsinA might 
play an important role to regulate and maintain an anatomically or structurally precise 
neurite orientation.  
 
TorsinA might also play a role to maintain nuclear envelope architecture and 
positioning.  First of all, mutant torsinA tends to accumulate in the lumen of the nuclear 
envelope; however, wild-type torsinA is predisposed to stay in the lumen of ER 
(Goodchild and Dauer, 2005; Hewett et al., 2006; 2007; Nery et al., 2007).  Next, torsinA 
interacts with lamin-associated polypeptide 1 (LAP1) in the nuclear envelope and 
lumenal domain-like LAP1 (LULL1) in the endoplasmic reticulum (Goodchild and 
Dauer, 2005).  In a more recent work, torsinA was found to localize to a protein complex 
that contained several cytoskeletal complexes including motor protein kinesin light chain, 
LAP1, LULL1, plectin, and nesprin (Hewett et al., 2006; Nery et al., 2007).  Plectin is an 
anchoring protein that associates with all three major components of the cytoskeleton for 
cross-linking (Liu et al., 1996).  Nesprin is the outer nuclear membrane protein that 
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interacts with cytoskeleton elements or the linker protein plectin (Wilhelmsen et al., 
2005).  The coordinated function of cytoskeletal and nuclear envelope proteins is very 
important for nuclear positioning and cell migration.  TorsinA knock-out and 
homozygous ΔGAG knock-in mice develop blebs in the nuclear envelope, which 
protrude from the inner nuclear membrane (Goodchild et al., 2005).  Furthermore, OOC-
5, a torsinA homologue in C. elegans, plays an essential role in PAR protein localization.  
The PAR family of proteins is essential for cellular polarity and partition establishment, 
and localization.  Mutations of ooc-5 result in an abnormal nuclear rotation and polarity 
in C. elegans embryos (Basham and Rose, 1999; 2001).    
 
Recent studies point out a critical role for torsinA in regulating protein secretion 
and synaptic vesicle recycling.  Hewett and colleagues (2007; 2008) reported that protein 
secretion processes were compromised in fibroblasts from DYT1 patients, and that 
attenuation of mutant torsinA expression restored protein secretion in DYT1 fibroblasts.  
In closely related work, Granata and colleagues (2008) found that an overexpression of 
wild-type torsinA attenuated synaptic vesicle recycling, whereas an overexpression of 
ΔE-torsinA intensified synaptic vesicle recycling at the expense of specificity.   
 
TorsinA has a highly homologous family member torsinB, which is encoded by 
TOR1B located adjacent to TOR1A on human chromosome 9q34 (Hewett et al., 2004).  
TorsinB shares 61% amino acid identity with torsinA.  Like torsinA, torsinB also harbors 
a AAA+ domain along with several glycosylation and phosphorylation sites (Hewett et 
al., 2004; O'Farrell et al., 2004).  TorsinB is expressed in the neurons and is enriched at 
the nuclear envelope (Hewett et al., 2004; O'Farrell et al., 2004).   In 
immunoprecipitation studies, torsinB was found to be associated with torsinA (Hewett et 
al., 2004), which suggested the possibility that torsinA and torsinB interact at a functional 
level.  However, the developmental expression patterns of these two proteins are 
divergent with striking expression of torsinA during the prenatal and early postnatal 
periods, and prominent expression of torsinB during late the postnatal period and 
adulthood (Vasudevan et al., 2006).  In summary, although torsinA and torsinB exhibit 
important structural similarities, torsinB can not completely compensate for the loss of 
torsinA since DYT1 knock-out mice die shortly after birth (Goodchild et al., 2005). 
 
Although various studies have been done to disclose the function of torsinA, and a 
heterogeneous function of torsinA has been reported, the systems biology of torsinA, and 
the causal effect of mutant torsinA to dystonia, are still unclear.  Genetically modified 
animal models are useful tools to investigate the contributing effects of mutant torsinA to 
the onset of DYT1 dystonia and to open the door for future studies.  
 
 
1.4 ANIMAL MODELS OF DYT1 DYSTONIA 
 
Several murine models of DYT1 dystonia have been developed, and characterized 
to various degrees (Dang et al., 2005; Goodchild et al., 2005; Sharma et al., 2005; 
Shashidharan et al., 2005; Dang et al., 2006; Grundmann et al., 2007; Yokoi et al., 2008).  
These models include DYT1 knock-out (Goodchild et al., 2005), cortex-specific DYT1 
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knock-out (Yokoi et al., 2008), torsinA knock-down (Dang et al., 2006), transgenic 
overexpression of mutant and wild-type torsinA (Sharma et al., 2005; Shashidharan et al., 
2005; Grundmann et al., 2007), and DYT1 ΔGAG knock-in (Dang et al., 2005; 
Goodchild et al., 2005) mouse models.  In the DYT1 ΔGAG knock-in mouse model, a 
GAA trinucleotide deletion was made to mimic the GAG deletion in human DYT1 
mutation, which was supposed to encode one of the glutamic acids at the position 
corresponding to human E302/303.  In addition, the expression of the DYT1 ΔGAG 
transcript was confirmed with RT-PCR and sequencing. 
 
Whereas common features exist among some of these models, inconsistent 
findings have been noticed (Table 1-2).  In addition, a comprehensive behavioral, 
neurochemical, and brain metabolical evaluation are needed for all the models.  TOR1A 
knock-out and homozygous TOR1A ΔGAG knock-in are embryonically or early 
postnatally lethal (Dang et al., 2005; Goodchild et al., 2005); morphological studies of 
these mice revealed neuronal-specific nuclear envelope vesicles, which appeared to 
derive from the inner nuclear membrane.  Dang and colleagues (2005) evaluated the 
behavioral, morphological, and neurochemical features of heterozygous ΔGAG knock-in 
mice.  They discovered abnormal motor behaviors in 6-month old male heterozygous 
ΔGAG knock-in mice, including horizontal hyperactivity in the open-field test, increased 
slips on the beam-walking test, and increased overlap in the foot-print analysis.  They 
also noticed ubiquitin- and torsinA-positive aggregates in neurons of the pontine nuclei 
and attenuated striatal homovanillic acid (HVA) levels in male heterozygous ΔGAG 
knock-in mice.  In the DYT1 knock-down model, motor deficits such as horizontal 
hyperactivity and increased slips on the beam-walking test were also noticed with 
reduced striatal DOPAC in a neurochemical study (Dang et al., 2006).  These findings 
suggest that torsinA is an essential protein for postnatal survival, and that ΔGAG is a loss 
of function mutation.  In a more recent study, similar motor deficits were reported in a 
cortex-specific DYT1 knock-out model (Yokoi et al., 2008).  The authors suggest that 
loss of torsinA in the cerebral cortex alone is sufficient to mimic behavioral deficits 
noticed in heterozygous ΔGAG knock-in and DYT1 knock-down mice. 
 
Transgenic models of DYT1 dystonia have been developed by Sharma et al. 
(2005), Shashidharan et al. (2005), and Grundmann et al. (2007).  Shashidharan and 
colleagues (2005) reported that 40% of their ΔGAG transgenic mice displayed dystonic 
movements of the limbs with self-clasping, circling behavior, and hyperactivity.  They 
also found ubiquitin- and torsinA-positive inclusions in the PPN, pons, and PAG, and a 
decreased striatal DOPAC/DA ratio in ΔGAG transgenic mice with a decreased striatal 
DA only in manifesting transgenic mice.  The ΔGAG transgenic mice developed by 
Sharma and colleagues (2005) showed a reduced ability to learn motor skills in an 
accelerating rotarod paradigm at six months of age, as well as abnormal dopaminergic D2 
receptor responses in striatal cholinergic interneurons (Pisani et al., 2006) and an 
attenuated amphetamine-induced striatal DA release (Balcioglu et al., 2007).  In a more 
recent study, Grundmann and colleagues (2007) generated another DYT1 transgenic 
model, in which torsinA expression was driven by a murine prion protein promoter.  
They found behavioral, morphological, and neurochemical abnormalities in ΔGAG 
transgenic mice (GAG3, a hΔGAG transgenic line) and wild-type transgenic mice  
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Table 1-2.  Murine DYT1 models. 
 
Model Molecular construct Morphology Behavior Neurochemistry 
DYT1 transgenic  
(Shashidharan et al., 
2005) 
 
 
7.1 kb fragment from the  
pNSE-Ex4 vector containing the 
neuron specific enolase promoter, 
human mutant (ΔGAG) torsinA-
cDNA and SV40 polyA signal 
 
 
ubiquitin- and torsinA-IR 
perinuclear aggregates 
and/or inclusion in the 
pedunculopontine nucleus, 
pons & periaqueductal 
gray 
40% of transgenic mice from 
each line displayed dystonic 
movements of the limbs with 
self-clasping, circling 
behavior, & 
hyperactivity 
↓ striatal DA in 
transgenic animals that 
exhibited an abnormal 
behavioral phenotype, ↓ 
striatal DOPAC/DA ratio 
in all transgenic mice 
DYT1 transgenic 
(Sharma et al., 2005) 
 
human wildtype (hWT) or mutant 
(ΔGAG) torsinA-cDNAs were 
inserted into pcDNA3.1 under the 
human cytomegalovirus immediate 
early promoter. 
 
no torsinA-positive 
inclusions or increased 
staining around the nuclear 
envelope (NE) 
reduced ability to learn motor 
skills in an accelerating 
rotarod paradigm 
↓ amphetamine-induced 
striatal extracellular DA 
levels 
DYT1 knock-in  
(Dang et al., 2005) 
Exon 5 in the targeting vector 
construct carries a GAA deletion at 
codon 302. The PGKNeoSTOP 
cassette with a false translation 
signal, splice donor site, and an 
additional poly(A) tail was inserted 
into intron 4.  
 
ubiquitin- and torsinA-
containing aggregates in 
pontine nuclei of male 
DTY1 knock-in mice 
deficient performance on the 
beam-walking test, open-field 
hyperactivity 
↓ striatal HVA 
DYT1 knock-out 
(Goodchild et al., 
2005) 
Exons 2-4 of Tor1a were replaced 
by a cassette containing Neo and 
IRES-tau LacZ sequences 
vesicles within the 
neuronal NE that appear to 
derive from the inner 
nuclear membrane 
 
  
DYT1 knock-in 
(Goodchild et al., 
2005) 
Exon 5 in the targeting construct 
carries a GAG deletion. Neo 
cassette was inserted into intron 4 
of Tor1a. 
 
homozygotes exhibit 
vesicles within the 
neuronal NE that appear to 
derive from the inner 
nuclear membrane 
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Table 1-2.  (Continued). 
 
Model Molecular construct Morphology Behavior Neurochemistry 
TOR1A knock-down 
(Dang et al., 2006) 
PGKNeoSTOP cassette with a false 
translation signal, splice donor site, 
and an additional poly(A) tail was 
inserted into intron 4 of Tor1a and 
recombination occurred 5' to an 
Exon 5 GAA deletion 
 
 horizontal hyperactivity,  
↑ slips on a beam-walking 
test 
↓ striatal DOPAC 
DYT1 transgenic 
(Grundmann et al., 
2007) 
human wild-type (hWT) and mutant 
(hΔGAG) torsinA-cDNAs were 
inserted into pBluescript II SK-
vector under the 3.4 kb fragment of 
the murine prion protein promoter 
and tagged C-terminally with V5-
His  
 
inclusion-like formation in 
brainstem nuclei , torsinA-
IR localized to the NE, and 
NE abnormalities in both 
hWT and hΔGAG mice 
hWT mice:  hypoactivity, 
short stride length, prolonged 
traversal times on beam 
walking 
hΔGAG mice: hyperactive, 
defects on rotarod testing 
hWT mice:  ↓ striatal 
DA, 5-HT and 5-HIAA;  
↓ brainstem HVA 
hΔGAG mice: ↑ 
brainstem DOPAC, 5-HT 
and 5-HIAA 
Cerebral Cortex-
specific DYT1 
Knock-out  
(Yokoi et al., 2008) 
Exons 3-4 of Tor1a were deleted by 
Emx1-cre in cerebral cortex 
reduction of torsinA-IR in 
the cortical layers 
↓ hind base width in male 
↑ slips on a beam-walking 
open-field hyperactivity 
more revolutions 
or circling behaviors 
No change 
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(WT24, a hWT transgenic line).  The GAG3 mice showed deficient performance on 
rotarod testing and hyperactivity in open-field tests as well as inclusion bodies in 
brainstem nuclei and nuclear envelope vesicles in brainstem and striatum.  
Neurochemical analysis also revealed elevated levels of DOPAC, 5-HT, and 5-
hydroxyindoleacetic acid (5-HIAA) in the brainstem of GAG3 mice.  The behavioral 
abnormalities noticed in WT24 mice included prolonged traversal times on beam-
walking, shorter stride length on foot-print analysis, and hypoactivity on open-field tests.  
WT24 mice also exhibited inclusion bodies in brainstem nuclei and nuclear envelope 
vesicles in brainstem and striatum.  In contrast to GAG3 mice, neurochemical studies 
revealed reductions in striatal DA, 5-HT, 5-HIAA, and brainstem HVA in WT24 mice.   
 
 
1.5 EXOGENOUS FACTORS 
 
 
1.5.1 Perturbations and Secondary Dystonia 
 
Trauma to the central nervous system (CNS) and periphery are established causes 
of secondary dystonia (Schott, 1985; Lee et al., 1994; Hollinger and Burgunder, 2000; 
Hummel and Lucking, 2001; LeDoux and Brady, 2003).  For example, Sankhla and 
colleagues  (1998) reported that 27 out of 160 subjects with oromandibular dystonia had a 
history of facial trauma, oromandibular surgery, or a dental procedure.  A previous 
history of head or face trauma with loss of consciousness occurred in 7.3% of cranial 
dystonia patients and 7.5% of extracranial dystonia patients in a case control study by 
Defazio et al. (1998).  The study by Defazio and colleagues also revealed that 12% of 
cervical dystonia patients had a history of neck or trunk trauma, and 25% blepharospasm 
patients had anterior-segment ocular diseases.   
 
Ischemic stroke is one of the more common causes of secondary dystonia 
(Jankovic and Van der Linden, 1988; Krystkowiak et al., 1998; Alarcon et al., 2004).  
Ischemic strokes that affected the striatum, globus pallidus, and thalamus have been 
clinically associated with the appearance of dystonic symptoms (Krystkowiak et al., 
1998; LeDoux and Brady, 2003).  Alarcon and colleagues (2004) did a cohort study on 
stroke and reported that 16 out of 1500 patients developed dystonia up to one year after 
either ischemic or hemorrhagic stroke.   
 
Prescription drugs and neurotoxins are other well-known causes of secondary 
dystonia (Liu et al., 1992; He et al., 1995; van Harten et al., 1998; van Harten et al., 1999; 
Johnson et al., 2000).  Neuroleptic drugs can precipitate acute dystonic reactions.  The 
risk for neuroleptic-induced dystonia is modified by risk factors such as age, gender, and 
concomitant medications (Remington et al., 1990; Khanna et al., 1992; van Harten et al., 
1999).  In a study, cocaine was reported to be a risk factor for neuroleptic-induced 
dystonia (van Harten et al., 1998).  A neurotoxin, 3-nitropropionic acid (3-NPA), 
produced by the fungus Arthrinium, often present in moldy sugarcane, was also noted to 
induce delayed dystonia (Liu et al., 1992; He et al., 1995; Johnson et al., 2000).   
Analyses of the secondary dystonias suggest that dopaminergic systems contribute to the 
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pathophysiology of this movement disorder in a subset of cases.  In many patients, 
lesions or insults involve widespread insults to the nervous system.   
 
 
1.5.2 Inciting Factors of Primary Dystonia 
 
Environmental factors are clearly associated with the development of primary 
adult-onset dystonias.  Repetitive highly skilled tasks such as writing or playing a string 
instrument significantly increase the risk of developing task-specific focal hand dystonia 
(Chen and Hallett, 1998).  Interestingly, scoliosis is a risk factor of cervical dystonia, 
possibly via compensatory alterations in head postures (Defazio et al., 2003).  
Alternatively, scoliosis could simply be the manifestation of axial dystonia, which 
precedes the development of adult-onset cervical dystonia.  Measles, mumps, or upper 
respiratory tract infections appear to be associated with the onset of spasmodic dysphonia 
(Schweinfurth et al., 2002).  Defazio and colleagues (1999) also reported that prior head 
or face trauma with loss of consciousness was a risk factor for the spread of 
blepharospasm.  Another group also reported that, in a cohort study of young onset 
primary cervical dystonia, 17.1% had been exposed to prior neck injury or surgery 
(Koukouni et al., 2007).  Thus, acute trauma and chronic repetitive use strain might 
precipitate dystonia in genetically predisposed individuals.  
 
 
1.6 SIGNIFICANCE OF THE STUDY 
 
Although the association of the GAG deletion in T0R1A and mutant torsinA with 
generalized dystonia has been known for over a decade, most work with torsinA has been 
done in cultured cells.  The systems biology of torsinA has been largely ignored.  
Because the DYT1 dystonia is penetrated in only 30-40% of carriers (Ozelius et al., 
1997), genetic modifiers and/or environmental factors might trigger the onset of DYT1 
dystonia in genetically predisposed individuals.  Relatively common perturbations (e.g., 
severe febrile illnesses, perinatal hypoxia, trauma, and intense sensorimotor training), 
which may affect either the CNS or PNS, occur with variable frequency and severity 
among DYT1 mutation carriers, and might trigger the onset of dystonic symptoms in 
perturbation-exposed DYT1 carriers.  To understand the systems biology of torsinA after 
central and peripheral insults, we examined torsinA expression following transient 
forebrain ischemia and sciatic nerve transection, respectively.  Our results, as described 
in Chapter 2, provide evidence that torsinA participates in the response of neural tissue to 
central and peripheral insults.  By extrapolation, lower perturbation-induced expression 
of functional torsinA might possibly contribute to the appearance of DYT1 dystonia in 
mutation carriers.   
 
 The behavioral, pathological, and neurochemical consequences of mutant torsinA 
have not been vigorously explored in the CNS.   For example, postmortem 
neuropathological and neurochemical studies have been limited to a few human DYT1 
brains, and have not been confirmed in replicate studies (Augood et al., 2002; Rostasy et 
al., 2003).  Due to a limited availability of human postmortem tissues, genetically 
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modified animal models provide useful models to investigate and confirm findings in 
human patients and to open the door for future studies.  In Chapter 3, transgenic mouse 
models that overexpress either human wild-type torsinA (hWT) or human mutant torsinA 
(hMT; two lines hMT1 and hMT2) were employed for behavioral, morphological, 
neurochemical, and metabolic examination of the DYT1 carrier state.  This work is 
important because it identifies important regions and pathways that might be critical to 
the systems pathophysiology of DYT1 dystonia.  On the other hand, some of the findings 
reported in Chapter 3 might simply be compensatory responses to the burden of mutant 
torsinA and the DYT1 genotype.  In either case, the data presented in Chapter 3 might 
provide important insights into the underpinnings of DYT1 dystonia.
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CHAPTER 2. TORSINA EXPRESSION AFTER NEURAL PERTURBATIONS 
TO THE CENTRAL AND PERIPHERAL NERVOUS SYSTEMS* 
 
 
2.1 INTRODUCTION 
 
TorsinA is an ER-resident glycoprotein, in which a single glutamic acid deletion 
in amino acid 302/303 is associated with the development of early-onset primary 
generalized dystonia (Ozelius et al., 1997).  The molecular and cellular functions of 
torsinA are essential for survial but are not well-understood.  The primary amino acid 
sequence of torsinA placed it within the AAA+ superfamily (Ozelius et al., 1997; 1999) 
and, as such, torsinA might function as a molecular chaperone.   
 
A variety of studies have provided evidence that torsinA is a chaperone for 
protein quality control and protein degradation.  TorsinA has been found localized with 
protein aggregations such as Lewy bodies and polyglutamine-containing neuronal 
inclusions in postmortem human brain (Shashidharan et al., 2000b; Sharma et al., 2001; 
Walker et al., 2003).  Overexpression of torsinA suppressed the formation of protein 
aggregates in cellular and C. elegans models (McLean et al., 2002; Caldwell et al., 2003).  
Overexpression of torsinA was also found to facilitate clearance of another dystonia-
related protein, SGCE, by the ubiquitin-proteosome system (Esapa et al., 2007).  
Moreover, torsinA expression was up-regulated after oxidative stress in PC12 cells and 
dopaminergic neurons in the substantia nigra pars compacta (Hewett et al., 2003; Kuner 
et al., 2004).  Overexpression of torsinA protects COS-1 and PC12 cells against a variety 
of cellular insults (Kuner et al., 2003; Shashidharan et al., 2004).  Similarly, 
overexpression of torsinA protects dopaminergic neurons from oxidative stress in C. 
elegans (Cao et al., 2005).   
 
TorsinA might also modulate the cellular trafficking of polytopic proteins such as 
dopamine transporter (Torres et al., 2004; Cao et al., 2005), as well as other membrane-
bound proteins, including G protein-coupled receptors, transporters, and ion channels 
(Torres et al., 2004).  TorsinA might, however, play more than one role in cells.  In 
particular, several lines of evidence suggest that torsinA might be part of the molecular 
machinery required to maintain nuclear envelope architecture and position, and to 
regulate neurite extension, protein secretion, and synaptic vesicle transport (Ferrari-
Toninelli et al., 2004; Goodchild and Dauer, 2005; Hewett et al., 2006; 2007; Granata et 
al., 2008; Hewett et al., 2008).    
 
When overexpressed in cells, mutant torsinA is concentrated at the nuclear 
envelope and tends to form perinuclear inclusion bodies (Hewett et al., 2000; Bragg et al., 
2004).  Mutant torsinA has reduced ATPase activity (Konakova and Pulst, 2005; Pham et 
                                                 
* Permission to reproduce by International Brain Research Organization. Zhao Y, Xiao J, 
Ueda M, Wang Y, Hines M, Nowak TS Jr, LeDoux MS (2008) Glial elements contribute 
to stress-induced torsinA expression in the CNS and peripheral nervous system. 
Neuroscience. 155: 439-453.  
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al., 2006).  Accordingly, loss of normal function might be one consequence of the 
missing glutamic acid residue in torsinA (McLean et al., 2002; Caldwell et al., 2003; 
Hewett et al., 2006; 2007; Granata et al., 2008; Hewett et al., 2008).  However, the most 
deleterious result of mutant torsinA might be its dominant negative effects on wild-type 
torsinA (Torres et al., 2004; Cao et al., 2005; Hewett et al., 2008).   
 
Because penetration of the DYT1 dystonia is only 30-40% (Ozelius et al., 1997), 
environmental factors might contribute to the onset of dystonia in genetically predisposed 
individuals.  Trauma to the PNS and CNS (Schott, 1985; Lee et al., 1994; Sankhla et al., 
1998; Hollinger and Burgunder, 2000; Hummel and Lucking, 2001), drugs (Remington et 
al., 1990; Khanna et al., 1992; van Harten et al., 1998; van Harten et al., 1999), 
neurotoxins (Liu et al., 1992; He et al., 1995; Johnson et al., 2000), and stroke 
(Krystkowiak et al., 1998; Alarcon et al., 2004) are known causes of secondary dystonia.  
Environmental factors also correlate with the onset of primary adult-onset dystonias 
(Chen and Hallett, 1998; Schweinfurth et al., 2002; Defazio et al., 2003).  Because DYT1 
mutation carriers demonstrate variable phenotypes from primary generalized dystonia to 
adult-onset focal dystonia, DYT1 dystonia and sporadic adult-onset dystonia may share 
common environmental risk factors (Leube et al., 1999; Grundmann et al., 2003).  Based 
on this information, subclinical perturbations (e.g., fever, hypoxia, trauma, and intense 
sensorimotor training) to the CNS or PNS, which often occur in variable combinations 
and severity in DYT1 mutation carriers, might trigger the onset of early-onset generalized 
dystonia in perturbation-exposed carriers (Treves and Korczyn, 1986).  Despite these 
important clinical associations, little is known about the expression and localization of 
torsinA after neural perturbations in vivo.  Our study evaluated the temporal and spatial 
expression of torsinA in response to central and peripheral nervous system insults in 
models of transient forebrain ischemia and sciatic nerve transection, respectively.  
Insufficient response of functional torsinA to environment insults might contribute to the 
onset of DYT1 dystonia in DYT1 mutation carriers. 
 
 
2.2 METHODS 
 
 
2.2.1 Animals 
 
All experiments were performed in accordance with the National Institutes of 
Health’s Guide for the Care and Use of Laboratory Animals and with approval of the 
Institutional Animal Care and Use Committee.  Wistar rats (Hilltop Lab Animals, Inc., 
Scottdale, PA, USA) were used for transient forebrain ischemia because the effects of 4-
vessel occlusion (4-VO) have been well characterized in animals of this source and strain 
(Pulsinelli and Brierley, 1979; Ueda and Nowak, 2005).  The sciatic nerve transections 
were performed in Sprague-Dawley rats (Harlan, Indianapolis, IN, USA). 
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2.2.2 Transient Forebrain Ischemia 
 
Adult male Wistar rats (250 - 300 g) were subjected to transient 4-VO ischemia 
(Pulsinelli and Brierley, 1979) with direct current (DC) potential monitoring as 
previously described (Ueda and Nowak, 2005).  In brief, surgical procedures were carried 
out under general inhalational anesthesia with 1 - 2% halothane in 70% N2 and 30% O2.  
The vertebral arteries were electrocauterized at the first cervical segment, and Silastic 
occluding devices were placed around the common carotid arteries.  On the following 
day, rats were re-anesthetized and placed in a stereotaxic frame.  Epidural and rectal 
temperatures were monitored and maintained at 37°C.  Hippocampal DC potentials were 
recorded with glass microelectrodes.  The carotid occluding devices were tightened to 
produce cerebral ischemia, as verified by 10 - 20 mV shifts in DC potential.  All 
hemispheres included in these studies exhibited ischemic depolarizations of 7 - 9 min 
duration in hippocampus, previously shown to produce consistent loss of CA1 neurons 
(Ueda and Nowak, 2005).  After release of occlusions, scalp incisions were closed, and 
rats were allowed to recover from anesthesia.  Control rats underwent sham surgical 
procedures that included vertebral artery cauterization and electrode placement without 
carotid occlusion.   
 
Brain tissues for RNA extraction and in situ hybridization were obtained at five 
post-ischemic survival intervals (6 hr, 24 hr, 7 d, 14 d, and 21 d), whereas tissues for 
immunocytochemistry were collected at three post-ischemic survival intervals (24 hr, 7 d, 
and 14 d).   Preparations from three ischemic and three sham control rats were obtained at 
each survival interval.  
 
For RNA extraction and in situ hybridization, rats were anesthetized with 5% 
halothane prior to decapitation.  Brains were rapidly removed from the cranial vault and 
were sectioned in the mid-sagittal plane.  For in situ hybridization, hemispheres were 
frozen in isopentane (-40 °C), sectioned parasagittally at 16 μm, and stored at -80 °C in 
sealed slide boxes with desiccant capsules.  For RNA extraction, cerebellum, striatum, 
thalamus, hippocampus, and cerebral cortex were dissected from the hemisphere, and 
were homogenized in RNAwizTM (Ambion, Austin, TX, USA) on ice within 2 - 3 min 
after decapitation. 
 
For immunocytochemistry, rats were overdosed with pentobarbital (100 mg/kg, 
intraperitoneally [IP]) prior to transcardiac perfusion with heparinized saline, and 4% 
paraformaldehyde/0.1 M phosphate buffer (PB).  Brains were post-fixed for 2 hrs, 
blocked, and incubated in a cryoprotectant solution (30% sucrose/0.1 M PB, pH 7.4) for 
at least 48 hrs.  Blocks were sectioned at 20 μm, and were collected on SuperFrost®-Plus 
glass slides (Fisher Scientific, Pittsburgh, PA, USA).  
 
 
2.2.3 Sciatic Nerve Transection 
 
Three-month old male Sprague-Dawley rats (250-300 g) were subjected to left 
sciatic nerve transection under ketamine/xylazine (87/13 mg/kg, IP) anesthesia. The rat 
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sciatic nerve was readily identified in the posterior thigh between the vastus lateralis and 
caput vertebralis muscles. In each rat, the left sciatic nerve was completely transected 
except for the medial epineurium, which was left intact to allow for apposition of the cut 
ends to facilitate axonal regeneration. Wounds were closed, and animals were allowed to 
recover from anesthesia in individual cages.  Four age-, weight- and gender-matched non-
surgical control rats were only subjected to anesthesia.   Four surgical rats were employed 
at each of five post-transection intervals (24 hr, 3 d, 7 d, 14 d, and 28 d).  Three rats in 
each group were utilized for RNA extraction, and one was used for immunocytochemical 
examination of the dorsal root ganglia (DRG). 
 
For RNA extraction, rats were overdosed with pentobarbital (100 mg/kg, IP) prior 
to transcardiac perfusion with saline and RNAlater (Ambion) as described in LeDoux et 
al. (2006).  The vertebral column was sharply dissected from the remainder of the 
carcass, and was placed in a 50 ml conical tube that contained RNAlater. The vertebral 
column was kept moist with RNAlater, while the right and left lumbar (L3-L6) DRG 
were microsurgically isolated and collected into separate pools for subsequent RNA 
extraction. 
 
For immunocytochemistry, rats were overdosed with pentobarbital (100 mg/kg, 
IP) prior to transcardiac perfusion with heparinized saline and 4% paraformaldehyde/0.1 
M PB.  The vertebral column was dissected and kept moist with fixative, while the right 
and left lumbar (L4-L5) DRG were isolated and collected into separate vials.  DRG were 
post-fixed for an additional 2 hr, and transferred to a cryoprotectant solution for at least 
48 hr.  DRGs were sectioned at 15 μm with a cryostat, and were collected on 
SuperFrost®-Plus glass slides.  
 
 
2.2.4 Relative Quantitative Real-time RT-PCR (QRT-PCR) 
 
Relative levels of torsinA mRNA were established in all brain and DRG tissues 
collected for QRT-PCR.  The QRT-PCR detection of torsinA mRNA levels in brain 
regions was performed by Dr. Jianfeng Xiao in Dr. LeDoux’s lab.  In brief, total RNA 
was extracted with RNAwizTM.  RNA purity and concentration were analyzed with a 
NanoDrop® spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA).  
DNA was removed with DNA-freeTM (Ambion).  Reverse transcription was performed 
with RETROscriptTM (Ambion) kit with 200 ng total RNA as template. The reaction mix 
was incubated at 44 °C for 1 hr, and at 92 °C for 10 min.  QRT-PCR was performed with 
Taqman® probes (Applied Biosystems, Foster City, CA, USA) for the target gene 
(torsinA) and endogenous controls (18S rRNA for brain tissues and GAPDH for DRG).  
Primer and probe sequences are described in Table 2-1.  Of note, technical triplicates 
were performed on each sample, and median values were used for subsequent analyses. 
 
Differential expression of torsinA was determined with the comparative threshold 
cycle (CT) method.  In particular, the expression levels of torsinA transcript in the 
ischemic and sham brains at each post-ischemic interval were calculated relative to the 
mean CT value for the sham controls at the corresponding time points.  A two-factor 
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Table 2-1.  Probe and primers used for QRT-PCR, and primers used to generate in 
situ hybridization probes. 
 
Name Sequence (5’→3’) Locus Usage Product (bp) 
QF1  ggccgtgtcggtcttcaata  NM_153303 743– 762 nt  RT-PCR  
QR1  atagccacgggactgcatct  NM_153303 893– 874 nt  RT-PCR  
151 (with 
QF1) 
QPro  
6-FAM-
caagaacagtggcttctggcacagc
a-TAMRA  
NM_153303 
764– 789 nt  RT-PCR probe  
TOR1AF  aagcggagcctcagccgtga  NM_153303 180– 199 nt  antisense probe 1  
TOR1AR  gataatacgactcactatagggccacaaacaggtgtacata  
NM_153303 
423– 405 nt  antisense probe 1  
244 (with 
1AF) 
TOR1SF  gataatacgactcactatagggaagcggagcctcagccgtga  
NM_153303 
180– 199 nt  sense probe 1  
TOR1SR  ccacaaacaggtgtacata  NM_153303 423– 405 nt  sense probe 1  
244 (with 
1SF) 
TOR2AF aaggaccaattacagatgtggat  NM_153303 465– 487 nt  antisense probe 2  
TOR2AR  gataatacgactcactatagggccagggcgtgctccatgtct  
NM_153303 
744– 725 nt  antisense probe 2  
280 (with 
2AF) 
TOR2SF  gataatacgactcactatagggaaggaccaattacagatgtggat  
NM_153303 
465– 487 nt  sense probe 2  
TOR2SR  ccagggcgtgctccatgtct  NM_153303 744– 725 nt  sense probe 2  
280 (with 
2SF) 
TOR3AF  acaagaacagtggcttctggca  NM_153303 763– 784 nt  antisense probe 3  
TOR3AR  gataatacgactcactatagggaacacagtcttgcagccctt  
NM_153303 
991– 972 nt  antisense probe 3  
229 (with 
2AF) 
TOR3SF  gataatacgactcactatagggacaagaacagtggcttctggca  
NM_153303 
763– 784 nt  sense probe 3  
TOR3SR  aacacagtcttgcagccctt  NM_153303 991– 972 nt  sense probe 3  
229 (with 
2SF) 
ActinAF  agcaagagaggcatcctga  NM_031144 178–196 nt  
β-actin antisense 
probe  
ActinAR  gataatacgactcactatagggacaacacagcctggatggcta  
NM_031144 
421–401 nt  
β-actin antisense 
probe  
244 (with 
ActinAF) 
ActinSF  gataatacgactcactatagggagcaagagaggcatcctga  
NM_031144 
178–196 nt  
β-actin sense 
probe  
ActinSR  acaacacagcctggatggcta  NM_031144 421–401 nt  
β-actin sense 
probe  
244 (with 
ActinSF) 
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(treatment and post-ischemic interval) analysis of variance (ANOVA) was used for 
statistical analysis with SAS (SAS Institute, Cary, NC, USA). 
 
For relative quantitative analysis of torsinA mRNA in the DRG, expression levels 
were calculated in reference to the mean CT value for all right and left (L3-L6) DRG 
from the three non-surgical control rats.  One-factor ANOVAs were used for independent 
analysis of data from the right and left DRG.  Single degree-of-freedom post-hoc 
contrasts were limited to comparisons between individual post-surgical time points and 
ipsilateral control DRG.  Analysis of the ipsilateral (left) DRG at 28 d was limited to two 
rats bscause poor-quality RNA was obtained from the third animal in this group. 
 
 
2.2.5 In situ Hybridization 
 
Radiolabeled (35S-UTP) complementary RNA (cRNA) probes were used to 
localize torsinA transcript in cryostat sections of rat brain.  Primer pair sequences to 
make the radioactive probes are described in Table 2-1.  The detailed protocol is 
provided in Xiao et al. (2004).  In brief, probes were made by in vitro transcription with 
T7 RNA polymerase (Ambion).  After fixation, acetylation, and dehydration through a 
graded series of ethanol, slides were incubated overnight in the hybridization buffer with 
radioactive probes (final concentration - 3 x 104 cpm/µl).  After treatment with RNase A 
(Sigma-Aldrich, St. Louis, MO, USA) at 37 °C for 30 min followed by a high stringency 
wash at 60 °C for 1 h, slides were dehydrated and exposed to Kodak Biomax MR Film 
along with 14C Microscale™ autoradiography standards (RPA504, Amersham 
Biosciences, Piscataway, NJ, USA) for 5 days.  Each sheet of film was exposed to paired 
ischemia and sham microscopic slides.  Autoradiographic images were acquired in the 
transmission mode (ScanMaker 9800 XL, Microtek, Carson, CA, USA), and were 
imported into ImageJ (Java version of NIH Image, http://rsb.info.nih.gov/ij/) for region of 
interest (ROI) quantification of radioactivity.  Optical density (O.D.) was calibrated to the 
set of autoradiography standards to generate measures of radioactivity (nCi/g tissue) for 
each ROI.  Hippocampal ROIs include internal and external blades of the dentate granule 
cell layer (iDG, eDG), four regions of stratum pyramidale that encompassed CA1 (Z1C, 
Z2C) and CA3 (Z3C, Z4C), and stratum oriens (SO), stratum radiatum (SR) and stratum 
lacunosum-moleculare (SLM) of the CA1 region.  Signal was acquired from 15 pixels (3 
x 5 rectangle) in the center of each ROI, from seven sections per animal, and the average 
was expressed relative to the mean obtained from sham sections hybridized in each of the 
experimental runs.  Two-factor (treatment and post-ischemic interval) ANOVA was used 
for statistical analysis of relative radioactivity within each ROI. 
 
 
2.2.6 Immunocytochemistry 
 
The primary and secondary antibodies used for immunocytochemical studies are 
listed in Table 2-2.  Cryostat brain and DRG sections were collected in eight and six 
series, respectively. One series of slides was air-dried overnight, and was stained with 
cresyl violet (brain) or hematoxylin and eosin (DRG).  The other series were processed  
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Table 2-2.  Primary and secondary antibodies. 
 
Antibody name Type Target Concentration Source 
TA1 rabbit 
polyclonal 
torsinA 1:500 Dr. Vijaya 
Ramesh, Harvard 
Medical School 
D-M2A8 mouse 
monoclonal 
torsinA 1:300 Dr. Vijaya 
Ramesh, Harvard 
Medical School 
Anti-
somatostatin 
rabbit 
polyclonal 
somatostatin 1:250 Chemicon 
International, 
Temecula, CA, 
USA 
Parv-19 mouse 
monoclonal 
parvalbumin 1:1000 Sigma, St. Louis, 
MO, USA 
GA5 mouse 
monoclonal 
GFAP 1:500 Chemicon 
OX-42 mouse 
monoclonal 
microglia 1:500 Chemicon 
V9 mouse 
monoclonal 
vimentin 1:10 Abcam, 
Cambridge, MA, 
USA 
SY38 mouse 
monoclonal 
synaptophysin 1:100 Abcam 
biotinylated 
horse anti-
mouse 
horse 
polyclonal 
mouse IgG 
(H+L) 
1:500 Vector, 
Burlingame, CA, 
USA 
biotinylated goat 
anti-rabbit 
goat 
polyclonal 
rabbit IgG 
(H+L) 
1:500 Vector 
Cy2-tagged 
donkey anti-
mouse 
donkey 
polyclonal 
mouse IgG 
(H+L) 
1:250 Jackson 
ImmunoResearch 
Laboratories 
Cy2-tagged 
donkey anti-
rabbit 
donkey 
polyclonal 
rabbit IgG 
(H+L) 
1:250 Jackson 
ImmunoResearch 
Laboratories 
rhodamine red-
X-tagged 
donkey anti-
mouse 
donkey 
polyclonal 
mouse IgG 
(H+L) 
1:250 Jackson 
ImmunoResearch 
Laboratories 
rhodamine red-
X-tagged 
donkey anti-
rabbit 
donkey 
polyclonal 
rabbit IgG 
(H+L) 
1:250 Jackson 
ImmunoResearch 
Laboratories 
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for immunohistochemical detection of torsinA and biomarkers for hippocampal 
interneurons (somatostatin and parvalbumin), astrocytes (glial fibrillary acidic protein 
[GFAP]) microglia (OX-42), intermediate filaments (vimentin), and synaptic vesicles 
(synaptophysin).  Anatomically equivalent sections from animals that represented each of 
the three post-ischemic survival intervals and corresponding sham controls were 
processed simultaneously.  Ipsilateral and contralateral DRG sections from all post-
surgical intervals were processed as a group.   
 
For peroxidase-based detection of torsinA, sections were first incubated in the 
quenching buffer (10% methanol and 3% H2O2 in 0.02 M phosphate-buffered saline 
[PBS]) for 5 min.  Sections were blocked and permeabilized in PBS that contained 2% 
nonfat dry milk and 0.3% Triton X-100 (Sigma).  Sections were incubated overnight with 
primary antibody diluted in PBS with 3% normal serum (Jackson ImmunoResearch 
Laboratories, West Grove, PA, USA) and 0.1% Triton X-100.  Sections were incubated 
with biotinylated secondary antibody diluted in PBS with 2% normal serum and 0.1% 
Triton X-100 for 4 hrs, peroxidase-labeled streptavidin (Vector Laboratories, 
Burlingame, CA, USA) for 1 hr, and nickel-intensified diaminobenzidine (Vector 
Laboratories) for visualization.  Between each step, slides were thoroughly rinsed with 
PBS.  After the final rinse, slides were air-dried overnight, dehydrated, cleared, and 
coverslipped with Permount (Fisher Scientific). 
 
Double-label fluorescent immunocytochemistry was used to examine the 
relationships between torsinA and cell-type specific biomarkers (Table 2-2).  Two 
primary antibodies that recognized torsinA were used in these studies: a rabbit 
polyclonal, TA1, and a mouse monoclonal, D-M2AB.  When TA1 was employed, Cy2- 
or rhodamine red-X (RRX)-tagged donkey anti-rabbit secondary antibodies (Jackson 
ImmunoResearch Laboratories) were used to visualize torsinA-IR.  With D-M2A8, 
biotinylated horse anti-mouse was used as a secondary antibody followed by Cy2-tagged 
streptavidin (Jackson ImmunoResearch Laboratories).  Slides were thoroughly rinsed, 
dehydrated, cleared, and coverslipped with 1,3-diethyl-8-phenylxanthine (DPX; Sigma-
Aldrich) mounting medium.  Sections were visualized with epifluorescence (Leica 
DM6000, Leica Microsystems Inc, Bannockburn, IL, USA) and confocal laser-scanning 
(Bio-Rad Laboratories, Hercules, CA, USA) microscopes.  For consistency of 
illustration, all torsinA-IR was transferred to the RGB green channel, and other 
biomarker-IR to the RGB red channel within Adobe Photoshop (San Jose, CA, USA). 
 
 
2.3 RESULTS 
 
 
2.3.1 TorsinA Transcript Was Up-regulated after Transient Forebrain Ischemia 
 
QRT-PCR was performed to evaluate the spatial and temporal expression of 
torsinA mRNA after transient forebrain ischemia, with 18S rRNA as an endogenous 
control.  The efficiencies of torsinA (1.74) and 18S rRNA (1.75) amplification were 
practically identical; the slope of ΔCT versus log10 ng total RNA was 0.054.  The CT 
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values associated with torsinA and 18S rRNA amplification showed strong linear 
relationships with log10 ng total RNA (torsinA: R2=0.978; 18S rRNA: R2=0.990).  
 
Up-regulation of torsinA mRNA was not detected at the 6 hr post-ischemic 
interval.  However, torsinA mRNA levels were significantly elevated within 24 hr after 
ischemia in all regions tested (Figure 2-1).  Transcript levels remained elevated at 7 days 
in all regions, and declined toward sham values by 14 d in striatum, thalamus, and cortex, 
and by 21 d in cerebellum and hippocampus.  In hippocampus and cerebellum, there were 
strong overall effects of ischemia (hippocampus [F1, 20 = 21.63, P = 0.0002], cerebellum 
[F1, 20 = 13.12, P = 0.0017]), post-ischemic interval (hippocampus [F4, 20 = 5.24,  P = 
0.0047], cerebellum [F4, 20 = 4.17, P = 0.0129]), and their interaction (hippocampus [F4, 20 
= 5.34, P = 0.0043], cerebellum [F4, 20 = 4.48, P = 0.0095]) on torsinA mRNA levels 
(Figure 2-1).  In these two regions, increased expression of torsinA transcript was 
present at 24 hr, 7 d, and 14 d but not at 6 hr or 21 d.  In the other three regions 
examined, the effects of ischemia were also considerable (striatum [F1, 20 = 13.96, P = 
0.0013], thalamus [F1, 20 = 8.43, P = 0.0088], and cerebral cortex [F1, 20 = 17.72, P = 
0.0004]), although there were no significant effects of post-ischemic interval and the 
ischemia x post-ischemic interval interaction on the relative levels of torsinA transcript.  
As seen in Figure 2-1, individual contrasts between the ischemia and sham groups were 
significant (P < 0.05) in all regions tested at the 24 hr and 7 d post-ischemic intervals 
and, additionally, in cerebellum and hippocampus at the 14 d post-ischemic interval.  The 
degree of torsinA mRNA up-regulation was greatest in ischemic cerebral cortex and 
hippocampus (> 3-fold).  TorsinA mRNA up-regulation in thalamus and striatum was 
also substantial (> 2-fold compared to control).   
 
The distribution of torsinA mRNA expression determined by in situ hybridization 
was consistent with its generalized expression in major neuron populations.  And the 
torsinA hybridization signal was not grossly impacted following ischemia (Figure 2-2).  
The decline in signal, evident in the hippocampal CA1 pyramidal layer at longer post-
ischemic intervals, was consistent with the loss of these neurons.  In addition, a more 
diffuse increase in torsinA hybridization was apparent in hippocampal neuropil at 7 and 
14 days, as further supported by quantitative analyses. Among the nine hippocampal 
ROIs analyzed, SLM (F1, 16 = 18.13, P = 0.0006) and iDG (F1, 16 = 6.88, P = 0.0185) 
showed the largest overall effects of ischemia on relative torsinA radioactivity (Figure  
2-3).  The ischemia x post-ischemic interval interaction was also significant in iDG (F3, 16 
= 4.89, P = 0.0134) and SLM (F3, 16 = 5.71, P = 0.0074).  In SLM, for example, relative 
torsinA radioactivity was only increased at the 7 d post-ischemic interval.  In Z1C and 
Z2C, the effects of post-ischemic interval (F1, 16 = 13.03, P = 0.0001 and F1, 16 = 16.86, P 
= 0.0001, respectively) and the ischemia x post-ischemic interval interaction (F3, 16 = 
10.32, P = 0.0005; F3, 16 = 17.33, P = 0.0001) were highly significant due to the increased 
signal in post-ischemic tissue at 24 hr and decreased signal at 7 d.  Other noteworthy 
findings were the effects of ischemia in SR (F1, 16 = 9.26, P = 0.0077) and the ischemia x 
post-ischemic interval interaction in eDG (F1, 16 = 8.37, P = 0.0014).  Individual contrasts 
between the ischemia and sham groups showed that relative torsinA radioactivity first 
became elevated at the 24 hr post-ischemic interval in iDG, eDG, Z2C, and Z1C (P< 
0.05, for all).  At the 7 d post-ischemic interval, relative torsinA radioactivity was 
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Figure 2-1.  QRT-PCR analysis of regional torsinA expression after transient 
forebrain ischemia. 
TorsinA transcript levels in each brain region are expressed relative to the mean CT value 
for the sham controls at each time point.  A significant increase in torsinA transcript was 
observed in all regions at 24 hr and 7 d post-ischemic intervals, and persisted in 
cerebellum and hippocampus at 14 d.  Results are expressed as the mean ± SEM  (*, P < 
0.05 for the difference between ischemic and sham groups at each interval).  
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Figure 2-2.  In situ hybridization of torsinA. 
Representative parasagittal sections are illustrated for a sham control and at indicated 
post-ischemic intervals, together with higher-magnification images of the corresponding 
hippocampus. Evident changes included a decrease in torsinA expression in the CA1 
pyramidal cell layer at late post-ischemic intervals, accompanied by elevated signal in 
neighboring neuropil (arrow). Scale bars indicate 5 mm for whole-brain images and 500 
µm for hippocampal images. The upper panel identifies ROIs subjected to further 
quantitative analysis (see Figure 2-3) including the internal and external blades of the 
dentate granule cell layer (iDG, eDG); four regions of stratum pyramidale that encompass 
CA1 (Z1C, Z2C) and CA3 (Z3C, Z4C); and stratum oriens (SO), stratum radiatum (SR) 
and stratum lacunosum-moleculare (SLM) of the CA1 region. 
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Figure 2-3.  Quantitative in situ hybridization analysis of hippocampal torsinA 
transcript levels. 
TorsinA hybridization was determined in the ROIs indicated in Figure 2-3, and were 
expressed relative to the mean value for sham sections hybridized in each experimental 
run.  A slight but significant increase in torsinA transcript was observed in dentate 
granule cells (iDG and eDG) and CA1 neurons (Z1C and Z2C) at 24 hr after ischemia. 
Expression in the CA1 pyramidal layer decreased at later intervals, accompanied by 
increased expression in SR, SLM, and SO at 7 d. Results are expressed as the mean ± 
SEM (*, P < 0.05 for the difference between ischemic and sham groups at each post-
ischemic interval)
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significantly up-regulated in SO, SR and SLM (P < 0.05, for all), and down-regulated in 
Z2C and Z1C (P < 0.05, for both).  By 21 d post-ischemia, torsinA hybridization returned 
toward sham values in all regions except Z2C.    
 
Given  the possible relationship of SNpc functional abnormalities to the 
pathophysiology of DYT1 dystonia, SNpc torsinA transcript levels were evaluated with 
quantitative in situ hybridization.  As seen in Figure 2-4, there was a significant effect of 
ischemia, post-ischemic interval, and ischemia x post-ischemic interval (F1, 16 = 9.07, P = 
0.0083; F3, 16 = 3.73, P = 0.0332; F3, 16 = 4.55, P = 0.0173, respectively) on relative 
torsinA radioactivity in the SNpc.  In addition, individual contrasts between the ischemia 
and sham groups were significant (P < 0.05) at the 24 hr post-ischemic interval. 
 
 
2.3.2 TorsinA Was Up-regulated in Hippocampal Astrocytes and Interneurons 
 
Changes in torsinA immunocytochemistry were consistent with the hybridization 
results, and permitted signal localization to specific cell types.  The initial increase in 
torsinA-IR at 24 hr occurred in the major hippocampal neuron populations that exhibited 
endogenous expression, whereas later diffuse increases overlapped the distributions of 
glial activation and synaptophysin up-regulation that took place in regions of CA1 neuron 
loss (Figure 2-5). 
 
Double labeling (Figure 2-6) identified torsinA co-localization in GFAP-positive 
astrocytes but not OX-42-labeled microglia.  Additional cells strongly-IR for torsinA 
included parvalbumin and somatostatin-IR interneurons.  As seen in Figure 2-7, 
hippocampal somatostatin and parvalbumin interneurons were torsinA-IR in post-
ischemic and sham tissues.  However, after ischemia, the relative intensity of torsinA-IR 
was higher in these cell types than in adjacent neurons.  Many of the parvalbumin-IR 
interneurons were scattered among pyramidal cells in the hippocampal pyramidal cell 
layer and granule cells in the dentate gyrus whereas others were localized to the dentate 
hilus and near the edge of the SO.  Most of the somatostatin-IR interneurons were found 
in the dentate subgranular proliferative zone, dentate hilus, SO and the boundary region 
between the SR and SLM.   
 
As seen in Figure 2-8, torsinA-IR was increased in neurons in the subgranular 
proliferative zone and hilus of the dentate gyrus, and pyramidal cells of the CA2 and CA1 
regions at 24 hr post-ischemia.  At 7 d post-ischemia, torsinA-IR was mildly decreased in 
CA1 pyramidal cells, and increased in neurons in the subgranular proliferative zone and 
hilus of the dentate gyrus, CA3/CA2 pyramidal cells, and the cells in the SR.  In the 14 d 
post-ischemic hippocampus, robust torsinA-IR was apparent in cells scattered within the 
SR and hilus of the dentate gyrus, and moderately-IR cells were sparsely distributed 
within the SO. 
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Figure 2-4.  Quantitative in situ hybridization analysis of torsinA transcript levels in 
SNpc. 
TorsinA hybridization signal was expressed relative to the mean value for sham sections 
hybridized in each experimental run.  A small but significant increase in torsinA 
transcript was observed at 24 hr after ischemia. Results are expressed as the mean ± SEM 
(*, P < 0.05 for the difference between ischemic and sham groups at each post-ischemic 
interval). 
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Figure 2-5.  Distribution of torsinA immunoreactivity and comparison with other markers. 
Torsin A-IR was moderately increased in the major hippocampal neuron populations at the 24 hr post-ischemic interval, and 
overlapped the distributions of astrocyte (GFAP) and microglial (OX-42) activation and synaptophysin upregulation at later 
intervals.  Confocal gray scale images of fluorescent immunocytochemistry are shown for torsinA (antibody TA1), GFAP, and 
OX-42, and inverted gray-scale images of peroxidase detection are shown for synaptophysin.  Scale bar, 500 μm
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Figure 2-6.  Cellular localization of torsinA immunoreactivity in glia. 
High-magnification confocal images of double-label fluorescent immunocytochemistry 
for simultaneous detection of torsinA (green, right column gray scale) and cell markers 
GFAP, OX-42 (red, middle column gray scale) in post-ischemic (7 d) hippocampus. 
TorsinA co-localizes with GFAP-positive astrocytes but not OX-42-labeled microglia. 
Double-labeled cells appear yellow in the merged images. Scale bar, 50 µm. 
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Figure 2-7.  Cellular localization of torsinA immunoreactivity in interneurons. 
High-magnification confocal images of double-label fluorescent immunocytochemistry 
for simultaneous detection of torsinA (green, right column gray scale) and cell markers 
parvalbumin and somatostatin (red, middle column gray scale) in sham and post-ischemic 
(7 d) hippocampus. TorsinA-IR is prominent in neurons that express parvalbumin and 
somatostatin (arrows). Double-labeled cells appear yellow in the merged images. Scale 
bar=50 µm. 
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Figure 2-8.  Immunoperoxidase detection of torsinA in post-ischemic hippocampus. 
Using the TA1 polyclonal antibody, increased torsinA-IR was detected in the cells in the 
subgranular proliferative zone (arrow) and hilus of the dentate gyrus, and in the 
pyramidal cells in CA3 and CA2 region at all time points after ischemia, and in cells 
scattered within the SR and SO of CA1 at 14 d after ischemia. M, molecular layer; G, 
granule cell layer; and H, hilus of the dentate gyrus. Scale bar, 200 µm.   
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2.3.3 TorsinA Transcript and Protein Were Up-regulated in Bilateral DRG after 
Unilateral Sciatic Nerve Transection 
 
TorsinA mRNA expression was increased after sciatic nerve transection (Figure 
2-9), as assessed by QRT-PCR.   The amplification efficiencies for torsinA and GAPDH 
were 0.95 and 1.01, respectively, and the slope of ΔCT versus log10 ng total RNA was  
-0.043.  The CT values associated with torsinA and GAPDH amplification showed strong 
linear relationships with log10 ng total RNA (torsinA: R2 = 0.94; GAPDH: R2 = 0.99).  
The overall effect of sciatic nerve transection was robust in contralateral DRG (F5, 12 = 
8.31, P = 0.0015), but did not reach statistical significance in ipsilateral DRG (F5, 11 = 
2.47, P = 0.098).  Post-hoc contrasts showed that torsinA expression differed between the 
control and surgical groups in ipsilateral and contralateral DRG at 24 hr and 3 d (P < 
0.05, for all), with a significant increase that persisted in the contralateral DRG at 7 d (P 
< 0.05).  
 
In control DRG, torsinA-IR was detected in satellite cells, the somas of ganglion 
cells, and axons (Figure 2-10).  After sciatic nerve transection, torsinA-IR increased in 
ganglion and satellite cells ipsilateral to the lesion, but only in satellite cells 
contralaterally.  In ipsilateral ganglion cells, torsinA-IR was most prominent at 3 and 7 d 
after sciatic nerve transection.  GFAP-IR co-labeled torsinA-positive satellite cells 
(Figure 2-11). 
 
 
2.3.4 TorsinA and Vimentin Co-localize in Neuronal and Glial Elements in the 
CNS and PNS 
 
Given the apparent up-regulation of GFAP after CNS and PNS insults and 
prominent expression of torsinA in GFAP-IR reactive astrocytes and satellite cells, we 
elected to localize a closely related intermediate filament protein, vimentin, in 
hippocampus and DRG (Figure 2-12).   Vimentin-IR interneurons and reactive astrocytes 
were readily apparent in post-ischemic hippocampus.  In interneurons, vimentin-IR was 
diffuse and co-localized with torsinA-IR.  Although many reactive astrocytes expressed 
vimentin and torsinA, co-localization of vimentin- and torsinA-IR was weak in these 
cells.  After sciatic nerve transection, vimentin-IR was readily visualized in satellite cells 
of the ipsilateral and contralateral DRG. 
 
 
2.4 DISCUSSION 
 
In normal brain, expression of torsinA is high in neurons and low in glia, and its 
developmental regulation indicates that torsinA might play a role in postnatal 
maturational events in the CNS (Xiao et al., 2004).  The present results indicate an altered 
pattern of torsinA expression, which notably involved astroglial cell types, after 
challenges to the central and peripheral nervous systems.  The similar quantitative and 
temporal features of torsinA up-regulation after sciatic nerve transection and 4-VO 
suggest the presence of common transcriptional control mechanisms, as well as a 
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Figure 2-9.  Temporal profiles of torsinA mRNA expression in DRG after unilateral 
sciatic nerve transection. 
TorsinA mRNA expression levels in ipsilateral and contralateral DRGs were calculated 
in reference to the mean CT value for all DRG from control rats (C).  Prominent bilateral 
increases in torsinA transcript were observed bilaterally at 1 and 3 days. Symbols indicate 
the mean ± SEM (*, P < 0.05 for the difference between lesioned and control animals).
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Figure 2-10.  Immunocytochemical localization of torsinA expression in DRG after 
unilateral sciatic nerve transection. 
TorsinA-IR increases were detected ipsilaterally in both ganglion cells (G) and satellite 
cells (arrow), but only in satellite cells contralaterally.  C, non-surgical control.  Scale 
bar, 100 µm. 
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Figure 2-11.  Co-localization of torsinA and GFAP in satellite cells. 
Confocal images of fluorescent immunocytochemistry illustrate co-localization in 
satellite cells (arrow) of ipsilateral DRG 14 d after sciatic nerve transaction. Co-
localization appears yellow in the merged images. G, ganglion cell. Scale bar, 50 µm.
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Figure 2-12.  Co-localization of torsinA and vimentin after ischemia and sciatic 
nerve transection. 
Confocal images of fluorescent immunocytochemistry illustrate co-localization in a 
subset of CA3 interneurons and CA1 astrocytes in 7 d post-ischemic hippocampus.  
Vimentin also co-localizes with the component of torsinA expression in satellite cells 
(arrow) of ipsilateral DRG 14 d after sciatic nerve transection.  Co-localization appears 
yellow in the merged images. G, ganglion cell. Scale bars, 50 µm (top three panels) and 
25 µm (other panels). 
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common role for this protein in the reparative and/or adaptive responses to such 
perturbations.    
 
 
2.4.1 Post-ischemic TorsinA Expression in the CNS 
 
Brief durations of global ischemia such as those used in these studies resulted in a 
selective loss of hippocampal CA1 pyramidal cells and interneurons of dentate hilus 
(Pulsinelli et al., 1982a; Nishino and Nowak, 2004; Ueda and Nowak, 2005).  However, 
4-VO produces severe reductions in blood flow throughout forebrain structures, as wellas 
appreciable perfusion deficits in cerebellum and brainstem (Pulsinelli et al., 1982b).  The 
rapid, generalized increase in torsinA transcript levels throughout the brain (Figure 2-1) 
that maintain the distribution in major neuron populations seen in control brain (Figure 
2-2) appears to reflect a relatively homogeneous response to this initial ischemic insult.  
This parallels, in many respects, the acute post-ischemic induction of many ischemia-
responsive genes, including many heat shock proteins (Nowak, 1991; Kawagoe et al., 
1992; Xue et al., 1998; Nowak and Kiessling, 1999; Yagita et al., 2001; Tanaka et al., 
2002).  Studies in other in vivo and in vitro models also suggest a role for torsinA in 
response to oxidative stress (Hewett et al., 2003; Kuner et al., 2004; Cao et al., 2005).  
 
In contrast, the delayed component of torsinA increase includes prominent 
expression in reactive astrocytes in regions of hippocampus (e.g., CA1) known to 
undergo neuron loss and synaptic reorganization after ischemia (Arabadzisz and Freund, 
1999; Briones et al., 2004).  In agreement with previous work, astrocytic and microglial 
markers showed the most prominent post-ischemic response in the CA1 region (Schmidt-
Kastner et al., 1990; Morioka et al., 1991; Gottlieb and Matute, 1999).  Although not 
specifically evaluated in this study, the persistent modest increase in torsinA expression 
noted in cerebellum (Figure 2-1) might be a correlate of glial activation in response to 
Purkinje cell vulnerability that also has been described after global ischemia (Diemer and 
Siemkovicz, 1981).   
 
Astrocytes are believed to carry out protective functions such as maintenance of 
ionic homeostasis, prevention of excitotoxicity (via glutamate uptake), scavenging free 
radicals, provision of nutrients and growth factors, and support of synaptogenesis and 
neurogenesis (Panickar and Norenberg, 2005).  Astrocytes are associated with the 
synapses, enwrap many pre- and post-synaptic terminals, and facilitate synaptic 
formation and synaptic neurotransmitter release (Araque et al., 1999; Grosche et al., 
1999; Ventura and Harris, 1999; Riquelme et al., 2002; Liu et al., 2004; Sobkowicz et al., 
2006).  The up-regulation of torsinA in reactive astrocytes might facilitate one or more 
protective functions of astrocytes such as glutamate uptake via movement of the 
polytopic glutamate transporter to the cell surface.  Alternatively, torsinA might 
contribute to the morphological and topological changes that reactive astrocytes must 
undergo in order to facilitate synaptogenesis and network reorganization (Lepekhin et al., 
2001; Witcher et al., 2007). 
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These results also demonstrate an up-regulation of torsinA expression in surviving 
somatostatin- and parvalbumin-IR interneurons (Figure 2-7), which likely contribute to 
the partial maintenance of torsinA transcript levels in the CA1 stratum pyramidale at late 
post-ischemic intervals despite the death of most pyramidal neurons (Figure 2-3).  It is 
well established that parvalbumin-IR interneurons in the hippocampus are resistant to 
ischemic stress (Nitsch et al., 1989; Ferrer et al., 1995).  Similarly, somatostatin-IR 
interneurons in the CA1 region are also relatively resistant to ischemia (Bering and 
Johansen, 1993; Bering et al., 1997).  Surviving interneurons in the CA1 region undergo 
significant morphological changes, and may serve as substitute targets for Schaffer 
collateral and other excitatory synaptic input after hippocampal ischemia (Arabadzisz and 
Freund, 1999).  Accordingly, it is rational to postulate that torsinA might participate in 
structural changes and/or transport of cell surface receptors in these hippocampal 
interneurons.    
 
Transient global ischemia is followed by neurogenesis in the subgranular 
proliferative zone (Sharp et al., 2002; Kokaia and Lindvall, 2003), and there is some 
evidence to suggest a parallel response in the posterior periventricular zone adjacent to 
the hippocampus (Nakatomi et al., 2002).   Neuroblasts that originate from the 
subgranular proliferative zone give rise to neurons within the granule cell layer and 
GFAP-IR astrocytes in the dentate hilus.  Although BrdU labeling was not examined in 
this study, the numerous cells robustly-IR for torsinA in the subgranular proliferative 
zone (Figure 2-8) might be such neuroblasts.  Developmental profiles of torsinA 
transcript and protein expression are also consistent with a role for torsinA during 
neurogenesis in brain (Xiao et al., 2004). 
 
 
2.4.2 TorsinA in the Injured PNS  
 
TorsinA is constitutively expressed in the PNS, where it is present in neuronal and 
glia elements (ganglion and satellite cells, respectively) in the DRG.  After unilateral 
sciatic nerve transection, torsinA transcript increased bilaterally (Figure 2-9).  TorsinA 
immmunoreactivity was detected in both cell types in the DRG ipsilateral to the lesion, 
but was more prominently increased in satellite cells contralaterally (Figure 2-10).  
Bilateral effects of sciatic nerve transection are consistent with work from other 
laboratories. Ryoke and colleagues (2000) reported that a conditioning lesion (i.e., left 
sciatic nerve transection) enhanced expression of IL-1β and TGF-β in the contralateral 
DRG and promoted nerve regeneration.  Similarly, increased expression of four cytokines 
(IL-1β, TGF-β1, TNF-α, and IL-10) was apparent in contralateral DRG for up to 35 days 
after sciatic nerve transection (Ruohonen et al., 2002).  Up-regulation of torsinA in 
ipsilateral ganglion cells is consistent with its potential role in the response to cellular 
stress as noted above in the context of cerebral ischemia.  However, the mechanism for 
up-regulation of torsinA in contralateral satellite cells is less obvious.  Satellite cells 
appear to play important roles in the physiology of their contiguous ganglion cells 
(Dublin and Hanani, 2007; Kuo et al., 2007).  Satellite cells exhibit increased gap-
junction coupling in response to the ipsilateral application of noxious stimuli (Dublin and 
Hanani, 2007).  Up-regulation of p75 in satellite cells appears to be responsible for 
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sympathetic sprouting in the DRG after peripheral nerve lesions (Hu and McLachlan, 
2000).  Because unilateral sciatic nerve transection is associated with compensatory 
changes in gait and appendicular loads, up-regulation of torsinA in contralateral satellite 
cells could be related to the increased signaling demands on the adjacent ganglion cells.  
Alternatively, up-regulation of torsinA in satellite cells could be part of a generalized 
response to the surgical intervention, possibly due to plasma TGF-β.  Interestingly, work 
in Drosophila suggested that TGF-β signaling might be defective in DYT1 dystonia (Koh 
et al., 2004).  Over-expression of Smad2, a downstream effector of TGF- β, suppressed 
ultrastructural defects at the neuromuscular junction in ΔGAG human torsinA flies. 
 
 
2.4.3 TorsinA Function 
 
TorsinA protein is structurally related to the ClpB/Hsp100 family of proteins, 
which have been shown to have unfoldase activities (Hong and Vierling, 2000; 
Weibezahn et al., 2004; Ung et al., 2007).  According to the evidence that torsinA was 
found localized to protein aggregations such as Lewy bodies in Parkinson's disease brain 
and inclusion bodies in trinucleotide repeat diseases, and its overexpression facilitated 
clearance of the aggregates (Shashidharan et al., 2000b; Sharma et al., 2001; McLean et 
al., 2002; Walker et al., 2003; Caldwell et al., 2003) and overexpression of torsinA 
facilitated clearance of another dystonia-related protein, SGCE, by the ubiquitin 
proteosome system (Esapa et al., 2007), torsinA is hypothesized to play a similar role as 
an unfoldase in mammalian systems (McLean et al., 2002; Kuner et al., 2003).  
 
Several largely-independent lines of evidence indicate that torsinA contributes to 
the brain development and might regulate neurite extension and synaptic functioning.  
TorsinA was strikingly expressed in prenatal and early postnatal period, with the most 
intense expression in cerebellar Purkinje cells, striatal cholinergic interneurons, and SNpc 
dopaminergic neurons at postnatal day 14 (Xiao et al., 2004), a period of intense cellular 
migration, neurite extension, and synaptogenesis.  TorsinA knock-out and homozygous 
ΔGAG knock-in mice die shortly after birth (Goodchild et al., 2005).  TorsinA was found 
localized to the neurites and synapses (Augood et al., 2003; Konakova et al. 2001; 
Konakova and Pulst, 2001; Kuner et al., 2003; Kamm et al., 2004).  Overexpression of 
mutant torsinA inhibited neurite extension; however, attenuation of wild-type torsinA 
facilitated neurite extension (Ferrari-Toninelli et al., 2004; Hewett et al., 2006).  In 
addition, torsinA was found to interact with snapin, a SNARE-associated protein, and to 
control synaptic-vesicle recycling (Ilardi et al., 1999; Granata et al., 2008).  TorsinA was 
also interacted with kinesin light chain, a motor protein to transport cargos from cell body 
to synapses along microtubules (Kamm et al., 2004).   
 
Other evidence suggests that torsinA might maintain the structure of the nuclear 
envelope and endoplasmic reticulum by interacting with cytoskeletal proteins.  TorsinA 
knock-out, homozygous ΔGAG knock-in, and ΔGAG transgenic mice showed 
morphological abnormalities of the nuclear envelope (Goodchild et al., 2005; Grundmann 
et al., 2007).  TorsinA co-immunoprecipitates with a multi-molecular complex that 
includes cytoskeleton proteins (vimentin, tubulin, and actin), a motor protein (KLC1), 
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nuclear envelope proteins (LAP1 and nesprin), an endoplasmic reticulum protein 
(LULL1), and a linker protein (plectin) (Goodchild and Dauer, 2005; Hewett et al., 2006; 
Nery et al., 2007).  The linker protein plectin links the nuclear envelope to the 
cytoskeleton by an interaction with nesprin, an outer nuclear membrane protein 
(Wilhelmsen et al., 2005).  In vitro studies have shown that mutant torsinA interferes 
with cytoskeletal events that involve vimentin (Hewett et al., 2006).   Vimentin, a 
member of the intermediate filament family of proteins, is expressed in the developing 
brain (Sancho-Tello et al., 1995; Hutchins and Casagrande, 1989), and is also induced in 
reactive glia (Kindy et al., 1992; Braun et al., 1998).  Vimentin plays an important role in 
cellular morphology and organelle positioning (Goldman et al., 1996).   
 
 
2.5 CONCLUSIONS 
 
Neurodevelopmental abnormalities might be central to the pathobiology of DYT1 
dystonia, given that generalized dystonia rarely develops during adulthood in ΔGAG-
mutation carriers (Bressman et al., 2000; Carbon et al., 2008b).  On the other hand, the 
reduced penetrance of the ΔGAG TOR1A mutation suggests that a perturbation (e.g., 
trauma, hypoxia, severe febrile illness, intense sensorimotor training) to the CNS or PNS 
might be required for the appearance of a dystonic phenotype.  Hypoxic-ischemic insults 
are believed to be pathogenic in cases of dystonic cerebral palsy (Kyllerman, 1982; 
Treves and Korcyzyn, 1986; Cerovac et al., 2007), an example of secondary dystonia, 
and it is conceivable that perinatal factors such as hypoxia-ischemia might increase 
expressivity of dystonia in carriers of the DYT1 mutation.  Its well-demarcated gross 
anatomy and precise intrinsic connections make the post-ischemic rat hippocampus an 
ideal model system in which to study the reactive synaptogenesis, astrocytosis, and 
neurogenesis that follows the loss of CNS neurons, and sciatic nerve transection offers 
comparable advantages in the PNS.  The induction of torsinA in glia suggests a novel 
avenue through which to explore the cellular and systems pathopathophysiology of 
DYT1 dystonia.
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CHAPTER 3. BEHAVIOR, MORPHOLOGICAL, NEUROCHEMICAL, AND 
METABOLIC FEATURES OF DYT1 ΔGAG TRANSGENIC MICE* 
 
 
3.1 INTRODUCTION 
 
Although the cellular function of mutant torsinA has been explored with a variety 
of in vivo approaches, the data generated in these studies do not provide a clear link 
between the molecular biology of torsinA and the development of dystonia.  However, 
post-mortem studies have provided evidence that functional abnormalities and/or 
ultrastructural abnormalities rather than neurodegeneration underlie DYT1 dystonia and 
pointed to the nigrostriatal pathway as a potential site of neuropathological significance 
in human DYT1 dystonia.  Rostasy and colleagues (2003) failed to disclose any 
consistent evidence of neuronal loss, inflammation, or neurodegeneration in DTY1 
dystonia, but they did detect an increased nigral cell density along with somatic 
enlargement of nigral dopaminergic neurons in the brains of DYT1 dystonia patients.  A 
significant increase in DA turnover and a decline in dopamine D1 and D2 receptor 
binding have also been established in DYT1 dystonic striatum (Augood et al., 2002).  In 
addition, functional neuroimaging studies have identified an increased metabolic activity 
in the putamen, cerebellum, and SMA in carriers of the DYT1 mutation (Eidelberg, 1998; 
Carbon et al., 2004a).  Together with evidence of high-level expression of torsinA 
transcript and protein within dopaminergic neurons of the SNpc during brain 
development (Konakova et al., 2001; Konakova and Pulst, 2001; Augood et al., 2003; 
Oberlin et al., 2004; Xiao et al., 2004; Vasudevan et al., 2006), these findings suggest that 
torsinA might be important for nigrostriatal development and function, whereby a mutant 
and non-functional protein could lead to aberrant nigrostriatal function and the 
subsequent development of dystonia.    
 
Unfortunately, the above-noted dopaminergic aberrations in human DYT1 
dystonia have not been replicated in independent studies.  Furthermore, the available data 
are limited by the number of brains examined in each study (Augood et al., 2002; Rostasy 
et al., 2003; Asanuma et al., 2005).  Genetically modified animal models are useful tools 
to investigate the contributing effects of mutant torsinA to the onset of DYT1 dystonia, 
investigate and confirm findings in human patients, and open the door for future studies.   
 
Current thinking related to AAA+ proteins suggests that a single mutant torsinA 
molecule could disrupt assembly of functional torsinA homohexamers.  Accordingly, 
intense transgenic expression of mutant torsinA should interrupt the function of 
endogenous torsinA by interfering with formation of intact homohexamer.  On this 
background, Sharma and colleagues (2005)  developed the hMT1, hMT2, and hWT lines 
of mice.  In these transgenic mice, either human wild-type or mutant torsinA are driven 
by the human cytomegalovirus (CMV) immediate early promoter.  Because there is no 
                                                 
* Permission to reproduce by Elsevier Inc. Zhao Y, DeCuypere M, LeDoux MS (2008) 
Abnormal motor function and dopamine neurotransmission in DYT1 DeltaGAG 
transgenic mice. Exp Neurol. 210: 719-730. 
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tag added to the human torsinA cDNA in the expression vector, the expression of the 
exogenous gene cannot be evaluated in the transgenic mice.  However, previous studies 
have reported that CMV promoters drive widespread expression of exogenous genes in 
the neurons and astrocytes, (Fritschy et al., 1996; van den Pol and Ghosh, 1998).  
Furthermore, under the CMV promoter the cellular pattern of expression involves entire 
neuronal arbors, transcripts and their protein products are not restricted to aberrant 
cellular compartments (van den Pol and Ghosh, 1998).  Therefore, the models developed 
by Sharma colleagues are suitable for the study of DYT1 dystonia.  In previous work, 
transgenic mice that express mutant torsinA show reduced ability to learn motor skills in 
an accelerating rotarod paradigm at six months of age, as well as abnormal dopaminergic 
D2 receptor responses in striatal cholinergic interneurons (Pisani et al., 2006).  
Furthermore, amphetamine-induced DA release is attenuated in the hMT1 mice 
(Balcioglu et al., 2007).  Of note, the hMT1 and hMT2 mice do not exhibit dystonia.  
Moreover, no other murine model of DYT1 dystonia actually manifests dystonia.  These 
results are not entirely unexpected, because the penetrance of the human DYT1 ΔGAG 
mutation is less than 40%.  In conclusion, hMT mice can be viewed as models of the 
DYT1 carrier state. 
 
In the work described herein, we rigorously characterized the behavioral, 
morphological, neurochemical, and brain metabolical features of the hMT1 transgenic 
model of the DYT1 carrier state.  As shown below, the hMT1 line exhibits robust 
transgene expression.  Specifically, a comprehensive battery of behavorial tests was used 
to identify motor abnormalities in hMT1 mice.  Electron and confocal microscopy were 
employed to evaluate previous reports of neuronal nuclear bleb formation and ubiquitin-
positive cytoplasmic inclusions, respectively, in human DYT1 dystonia and other murine 
models of DYT1 dystonia (McNaught et al., 2004; Dang et al., 2005; Goodchild et al., 
2005; Shashidharan et al., 2005; Grundmann et al., 2007).  High-performance liquid 
chromatography with electrochemical detection (HPLC-EC) was carried out to 
comprehensively quantify monoaminergic neurotransmitters and their metabolites in 
multiple neural structures.  Finally, 2-deoxy-D-glucose (2-DG) utilization, as well as 
cytochrome oxidase (CO) histochemistry, was performed to evaluate short- and long-
term brain metabolic demands. 
 
 
3.2 METHODS 
 
 
3.2.1 DYT1 Transgenic Mouse Model and Genotyping 
 
Breeding colonies of hWT, hMT1, and hMT2 mice were established at the 
University of Tennessee Health Science Center by matings with wild-type (WT) 
C57BL/6J mice.  All mice used in experiments were C57BL/6J backcrossed at least 8X.  
Tail DNA from the breeders and their offspring were isolated with the AquaPure 
Genomic DNA Tissue Kit (Bio-Rad Laboratories, Hercules, CA, USA) for genotyping.  
The primer pair used for genotyping analysis is detailed in Table 3-1.  The primers 
amplified a 560-bp segment (35 cycles; annealing temperature - 60°C) within the human  
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Table 3-1.  Probe and primers used for QRT-PCR, and primers used for generation 
of Northern blot probes. 
 
Name Sequence (5’→3’) Locus Usage Product (bp) 
GF1 cacattgcactttccacatgct NM_000113 479 – 500 nt Genotyping  
GR1 cgttttgcagcctttatctga NM_000113 1040 – 1020 nt Genotyping 
560 (with 
GF1) 
TOR1AF gcgtctctactgcctcttcg NM_000113 197– 216 nt 
antisense probe 
1  
TOR1AR gataatacgactcactatagggtggacatagtcactgttcag 
NM_000113 
466– 447 nt 
antisense probe 
1 
270 (with 
1AF) 
TOR1SF gataatacgactcactataggggcgtctctactgcctcttcg 
NM_000113 
197– 216 nt sense probe 1  
TOR1SR tggacatagtcactgttcag NM_000113 466– 447 nt sense probe 1 
270 (with 
1AF) 
TOR2AF acaagaacagtggcttctggca NM_000113 817 – 838 nt 
antisense probe 
2  
TOR2AR gataatacgactcactatagggggtgaacaccgttttgcagc 
NM_000113 
1049 – 1030 nt 
antisense probe 
2 
233 (with 
2AF) 
TOR2SF gataatacgactcactatagggacaagaacagtggcttctggca 
NM_000113 
817 – 838 nt sense probe 2  
TOR2SR ggtgaacaccgttttgcagc NM_000113 1049 – 1030 nt sense probe 2 
233 (with 
2SF) 
Actb1AF agcaagagaggtatcctga NM_144884 257 – 275 nt 
β-actin 
antisense probe  
Actb1AR gataatacgactcactatagggacagcacagcctggatggcta 
NM_144884 
500–480 nt 
β-actin 
antisense probe 
244 (with 
Actb1AF) 
Actb1SF gataatacgactcactatagggagcaagagaggtatcctga 
NM_144884 
257 – 275 nt 
β-actin sense 
probe  
Actb1SR acagcacagcctggatggcta NM_144884 500–480 nt 
β-actin sense 
probe 
244 (with 
Actb1SF) 
QF1-h gcgtctctactgcctcttcg NM_000113 197 – 216 nt RT-PCR  
QR1-h ggttgtcgtccagatccttc NM_000113 282 – 263 nt RT-PCR 
86 (with 
QF1-h) 
QP1-h gggcagaag NM_000113 229 – 236 nt RT-PCR  
QF1-m ccgtgtcggtcttcaataaca NM_144884 769 – 789 nt RT-PCR  
QR1-m aataatctatgaggttccggtcaa 
NM_144884 
843 – 820 nt RT-PCR 
75 (with 
QF1-m) 
QP1-m cagcagcc NM_144884 809 – 816 nt RT-PCR  
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torsinA coding sequence that was identified via 1% agarose gel electrophoresis (Figure 
3-1A).  The genotype of the breeders was confirmed by restriction digestion with BseRI 
(New England BioLabs, Ipswich, MA, USA).  The human WT torsinA PCR product was 
digested with BseRI into four fragments (279 bp, 238 bp, 24 bp, and 22 bp).  The human 
mutant torsinA PCR product was digested with BseRI into three fragments (279 bp, 259 
bp, and 22 bp).  Fragment profiles were identified with 2% agarose gel electrophoresis 
(Figure 3-1B). 
 
 
3.2.2 Northern Blot Hybridization 
 
Whole-brain RNA from WT (n = 4), hWT (n = 4), hMT1 (n = 3), and hMT2 (n = 
4) mice were extracted with TRI reagent® (Ambion, Austin, TX, USA) and DNA was 
removed with DNA-freeTM.  Total RNA quality was examined with agarose gel 
electrophoresis and a NanoDrop® ND-1000 spectrophotometer.  Pooled human whole 
brain RNA was obtained from Ambion (Human Brain Reference RNA, n = 23 brains).  
The MicroPoly(A)Purist (Ambion) kit was used to extract mRNA from total RNA.  The 
mRNA was electrophoretically resolved on denaturing gels and transferred to positively 
charged nylon membranes.  Radiolabeled (32P-UTP) cRNA probes were generated by in 
vitro transcription with T7 RNA polymerase.  Primer pair sequences to make the 
radioactive probes are described in Table 3-1.  After ultraviolet crosslinking, blots were 
prehybridized and hybridized overnight with TOR1A and Actb (β-actin) cRNA probes.  
The TOR1A probe was generated from human cDNA template, whereas the Actb probe 
was generated from mouse cDNA template.  After washing, blots were exposed to Kodak 
Biomax MR radiographic film prior to development. 
 
 
3.2.3 QRT-PCR 
 
Reverse transcription was performed with Ambion's RETROscriptTM kit with 500 
ng total RNA as template. The reaction mixture was incubated at 44 ºC for 1 hr and at 92 
ºC for 10 min.  QRT-PCR was performed with the Roche LightCycler 480 with gene-
specific primers and Universal Taqman® probes (Table 3-1; Roche Applied Science, 
Indianapolis, IN, USA) for the target genes (human torsinA and mouse torsinA) and 
endogenous control (Cyclophilin D).  Relative levels of human torsinA transcript in 
mouse brain were calculated relative to Human Brain Reference RNA and total RNA 
from normal human striatum (Stratagene, La Jolla, CA, USA; n = 1 brain), whereas levels 
of mouse torsinA mRNA (hWT [n = 4], hMT1 [n = 3], and hMT2 [n = 4]) and striatal 
(hWT [n = 6], hMT1 [n = 8], and hMT2 [n = 4]) were calculated relative to WT 
littermates (whole brain [n = 4] and striatum [n = 6]).   
 
 
3.2.4 Behavioral Assessment 
 
Adult (3–4 month) male hWT (n = 24) and hMT1 (n = 35) mice, along with WT 
(n = 20) age- and gender-matched littermate controls, were used for quantitative analyses 
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Figure 3-1.  Genotyping and Northern blot analysis of hWT, hMT1, and hMT2 
transgenic mice. 
Gel images of PCR products before (A) and after (B) digestion are shown.  Products from 
hMT1 or hMT2 mice appear in lanes 1, 2, and 4, whereas products from hWT mice 
appear in lanes 3, 5, and 6.  (C) Northern blot analysis of equal amount of poly-A RNA 
obtained from brain tissues of human, WT, hWT, hMT1, and hMT2 mice.  Human 
torsinA probes recognized a 1.5 kb band in transgenic mice, and a 2.5 kb band in human 
brain.  Mouse β-actin (loading control) appeared as a 2.0 kb band below each lane.   
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of motor functions (Jiao et al., 2005).  In addition, hMT1, hMT2, and hWT mice, 
including animals over one year of age, were routinely observed for evidence of dystonia 
during open-field behavior.     
 
 
3.2.4.1 Rotarod Performance   
 
Mice were acclimated to a Rotamex-5 rotarod (Columbus Instruments, Columbus, 
OH, USA) that rotated at 5 rpm for 5 min one day prior to data acquisition.  Two motor 
assessments were performed.  The first assessment began with a 30 s acclimation period 
at 4 rpm, followed by an acceleration of 4 rpm every 30 s to a maximum of 5 min at 40 
rpm.  Mice were given three trials at the same time each day for 5 consecutive days.  The 
second assessment began with an initial speed of 4 rpm, which gradually accelerated at a 
rate of 1 rpm every 5 s to an incremented target speed for 5 consecutive days (5, 10, 20, 
30, and 40 rpm, respectively).  Transgenic and WT littermate mice were randomly 
selected for one of these two trials.  All tests were performed in technical triplicate, and 
median values were used for statistical comparison.  
 
 
3.2.4.2 Footprint Analysis 
 
Mouse forepaws (green) and hindpaws (red) were dipped in nontoxic water-based 
paints.  Mice were allowed to walk down an enclosed runway lined with white paper.  
Three trials were performed on three separate days within one week.  Two to four steps 
from the middle portion of each run were measured for (1) stride length, (2) hind-base 
width (the distance between the right and left hindlimb strides), and (3) front-base width 
(the distance between the right and left forelimb strides).  At least seven steps were 
measured for each mouse.  Mean values were used for statistical analysis. 
 
 
3.2.4.3 Tail Suspension  
 
This test involved the response of each mouse to 1 min of vertical suspension 
from the tail.  Neurological dysfunction is exhibited as hindlimb and/or forelimb clasping 
during this maneuver. 
 
 
3.2.4.4 Vertical Rope Climb 
 
Mice were acclimated to a vertical, 40-cm long, 10-mm thick nylon rope prior to 
testing.  The bottom of the rope was suspended 15 cm above a padded base, and the top 
entered into a darkened escape box.  Three trials with a 5-min intertrial interval were 
completed for each mouse.  Median times were used for statistical analysis. 
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3.2.4.5 Raised-beam Task   
 
Mice were acclimated to an 80-cm long, 20-mm wide beam elevated 50 cm above 
a padded base.  A 60W lamp at the start served as an aversive stimulus, whereas the 
opposite end of the beam entered a darkened escape box. Transversal time and number of 
slips were measured as mice traversed the beam.  After initial testing with a 20-mm 
diameter square beam, mice were given follow-up tests using supplementary round (8-
mm and 12-mm diameter) and square (12-mm diameter) beams.  All testing was 
performed in triplicate, and median values were used for subsequent statistical analyses. 
 
 
3.2.5 Confocal Microscopy 
 
Adult (3–4 month) male WT (n = 3), hWT (n = 3), and hMT1 (n = 3) mice were 
overdosed with pentobarbital (100 mg/kg, IP) prior to transcardiac perfusion with 
heparinized saline and 4% paraformaldehyde/0.1 M PB.  Brains were dissected, post-
fixed in 4% paraformaldehyde for another 2 hrs, and incubated in a cryoprotectant 
solution (30% sucrose/0.1 M PB, pH 7.4) for at least 48 hrs.  Brains were sectioned at 20 
μm on a cryostat, collected onto SuperFrost®-Plus glass slides, circled with a PAP pen, 
and allowed to dry on a slide warmer for 10 min.  Sections were blocked in 2% nonfat 
dry milk and 0.3% Triton X-100 in 0.02 M PBS, and incubated overnight with mouse 
monoclonal anti-torsinA antibody D-M2A8 (1:300 diluted in PBS with 3% normal 
donkey serum and 0.1% Triton X-100) and rabbit polyclonal anti-ubiquitin antibody 
(1:1000; Dakocytomation, Carpinteria, CA, USA).  Sections were incubated for 4 hr with 
biotinylated horse anti-mouse (1:500) and RRX- tagged donkey anti-rabbit secondary 
antibodies (1:250) diluted in PBS with 2% normal donkey serum and 0.1% Triton X-100.  
After rinsing with PBS, sections were incubated for 1 hr with Cy2-tagged streptavidin 
(1:500) diluted in PBS with 0.1% Triton X-100.  Sections were rinsed, air-dried, 
dehydrated, cleared, and coverslipped with DPX mounting compound.  Sections were 
visualized with epifluorescence (Leica DM6000) and confocal laser-scanning 
microscopy. 
 
 
3.2.6 Electron Microscopy 
 
Adult (3–4 month) male WT (n = 3), hWT (n = 3), and hMT1 (n = 3) mice were 
overdosed with pentobarbital (100 mg/kg, IP) prior to transcardiac perfusion with 
heparinized saline and 4% paraformaldehyde/2.5% glutaraldehyde/15% picric acid in 0.1 
M PB.  The brains and cervical spinal cords were dissected from surrounding tissue.  
Regions of interest (striatum, pons, cerebellar cortex, and spinal cord) were cut into 3 x 3 
x 3 mm blocks that were post-fixed overnight.  Tissue blocks were post-fixed in 1% 
osmium tetroxide (Electron Microscopy Sciences, Hatfield, PA, USA) in PBS for 4 hrs, 
and were rinsed briefly in deionized water.  After ascending dehydration in 30%, 50%, 
70%, 85%, 95%, and 3 X 100% ethanol (each for 30 min), tissue blocks were infiltrated 
with 50% Spurr (Electron Microscopy Sciences) in 100% ethanol overnight at room 
temperature, and 100% Spurr over 8 hrs.  Blocks were cured at 70 °C for 2 days.  One-
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micrometer sections were cut on a Reichert Ultracut E microtome (Reichert Instruments, 
Depew, NY, USA), and were stained with toluidine blue.  Areas of interest were selected, 
sectioned at 75 nm, mounted onto 150-mesh grids, and post-stained with 4% uranyl 
acetate in methanol and Venable lead citrate.  Sections were visualized, and were 
photographed with a JEOL 2000EX transmission electron microscope (JOEL USA Inc., 
Peabody, MA, USA) at 60 kV with 30,000X magnification.  
 
 
3.2.7 HPLC-EC Analysis of Monoamines and Their Metabolites 
 
All standards, including 5-HIAA, 5-HT hydrochloride, DA hydrochloride, 
DOPAC, epinephrine hydrochloride (EPI), HVA, and NE hydrochloride, were of 
analytical grade, and were purchased from Sigma-Aldrich.  Sodium octylsulphonate 
(SOS) and monobasic anhydrous sodium dihydrogen phosphate used in mobile-phase 
preparation were purchased from Fluka Chemie (Buchs, Switzerland).  HPLC-grade 
water and acetonitrile were obtained from Fisher Scientific. 
 
Tissues from adult (3-4 month) male hWT (n = 10) and hMT1 (n = 11) mice, 
along with WT (n = 10) age- and gender-matched littermate controls were analyzed with 
HPLC-EC to quantify cerebral cortical, striatal, and cerebellar levels of DA, NE, EPI, 5-
HT, DOPAC, HVA, and 5-HIAA.  
 
Fresh samples of striatum, cerebellar cortex, and cerebral cortex were weighed 
and homogenized in 100 μl of an ice-cold solution of 0.1 M perchloric acid, 0.1 mM 
sodium metabisulfite, and 0.1 mM EDTA per 10 mg wet weight.  Homogenates were 
centrifuged at 20,000 g for 25 min at 4 °C.  Supernatants were filtered through 0.22 µm 
pore size polyvinylidene fluoride syringe-driven membrane filters (Millipore Corp., 
Bedford, MA, USA), and the filtrate was immediately frozen and stored at -80 °C until 
the time of analysis.  
 
HPLC analysis was performed with an ESA Model 5600A CoulArray® system 
(ESA Inc., Chemlsford, MA, USA), equipped with Shimadzu Model DGU-14A on-line 
degassing unit (Shimadzu Scientific Instruments, Columbia, MD, USA), an ESA Model 
582 pump, and an ESA Model 542 refrigerated autosampler.  The detection system 
consisted of three coulometric array modules, and each contained four electrochemical 
detector cells.  Electrode potentials were selected over the range of +50 to +600 mV, with 
a 50 mV increment against palladium electrodes.  Chromatographic separation was 
achieved by auto-injecting 20 μl sample aliquots at 5 ºC onto a MetaChem Intersil 
(MetaChem Technologies, Torrance, CA, USA) reversed-phase C18 column (5 µm 
particle size, 250 x 4.6 mm I.D.) with an ESA Hypersil C18 guard column (5 µm particle 
size, 7.5 x 4.6 mm I.D.).  The mobile phase used for compound separation consisted of 75 
mM monobasic sodium dihydrogen phosphate, 2.0 mM SOS, 25 μM EDTA, 0.005% 
triethylamine, and 10% acetonitrile, pH 3.0.  A flow rate of 1.5 ml/min and analysis time 
of 45 min were used for all experiments.  System control and data acquisition/processing 
were performed with ESA CoulArray software (version 1.02).  All samples were 
processed in technical triplicate, and median values used for statistical analysis.   
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3.2.8 2-DG Autoradiography and CO Histochemistry 
 
 
3.2.8.1 Tissue Collection 
 
Adult (3–4 month) male hMT1 (N = 9) and hWT (N = 8) mice, along with WT (N 
= 9) age- and gender-matched littermate controls, were used for quantitative analyses of 
brain metabolism with 2-DG uptake and CO histochemistry.   
 
After a single dose of 2-DG (0.165 μCi/g) given by intraperitoneal injection, mice 
were placed in individual cages with free movement for 45 min to allow for 2-DG 
absorption, overdosed with pentobarbital, and perfused with heparinized saline followed 
by a mixture of 2.5% paraformaldehyde/1.5% glutaraldehyde/4% sucrose in 0.1 M PB.  
Brains were rapidly removed from the skull, blocked, rapidly frozen in isopentane (-40 
ºC), and stored at -80 ºC.   
 
Brains were sectioned in five series on a cryostat at 20 μm in the coronal plane.  
Sections were collected onto SuperFrost®-Plus glass slides and stored at -80 ºC in 
vacuum-sealed slide containers.  One series of sections was air-dried overnight and 
stained with cresyl violet.  Separate adjacent series were processed for 2-DG 
autoradiography imaging and CO histochemistry.  
 
 
3.2.8.2 Image Acquisition and Glucose Utilization (GU) Densitometric Analysis  
  
Brain sections were exposed to Kodak Biomax MR Film together with 14C 
Microscale™ autoradiography standards for 7 days.  Autoradiographic images were 
acquired in the transmission mode and were imported into ImageJ for ROI quantification 
of radioactivity.  Optical density (O.D.) was calibrated to the set of autoradiography 
standards to generate measures of radioactivity for each ROI.  ROIs were defined 
according to a widely-employed mouse brain atlas (Franklin and Paxinos, 1997).  Due to 
potential confounding variables such as peritoneal absorption, blood-brain permeability, 
and global utilization, ROI GU data from each mouse was converted to Z-scores.  
 
 
3.2.8.3 CO Histochemistry 
 
Our CO histochemistry protocol was modified from the protocol of Gonzalez-
Lima and Jones (1994).  The reaction solution was freshly made in 0.1 M PB (pH. 7.4) 
that contained 0.06% diaminobenzidine, 0.02% cytochrome c, and 4.5% sucrose.  Brain 
slides, together with brain-homogenate standards, were incubated in the reaction solution 
for 1.5 h in the dark at 37 ºC in a shaking water bath.  The reaction was stopped by 
washing the slides with 0.1M PB with 4% sucrose for 3x 5 min.  After dehydration in 
ascending concentrations of ethanol (30%, 50%, 75%, 95%, and 2 X 100%), the slides 
were cleared with xylene and were coversliped with Permount.  
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3.2.8.4 Preparation of CO Standards and Biochemical Assay of CO Activity 
 
Fresh whole brains from five wild-type C57BL/6J mice were homogenized with a 
manual Dounce-glass homogenizer without buffer.  The brain pastes were transferred to 2 
ml microcentrifuge tubes.  After centrifugation at 1000 rpm for 2 min at 4 ºC, the tubes 
were rapidly frozen in prechilled isopentane (-40 ºC) and were stored at -80 ºC. 
 
Brain pastes were sectioned on a cryostat in series of variable thickness that 
covered the entire range of CO activities measured in different brain structures (5 μm, 10 
μm, 20 μm, 30 μm, 40 μm, 50 μm, and 60 μm), collected onto SuperFrost®-Plus glass 
slides, and stored at -80 ºC in a vacuum-sealed slide container for further usage as CO 
activity standards. 
 
The CO activity of the brain pastes was determined with a spectrophotometric 
method modified from Hess and Pope (1953) by Gonzalez-Lima and Jones (1994).  First, 
the sample solution was generated by mixing the brain homogenate in 0.75% 
deoxycholate solution at ratio of 0.01g per 5 ml.  Next, 0.1 ml of the sample solution was 
added to 0.9 ml of 30 μM reduced cytochrome c solution and mixed well.  The O.D. was 
measured with a SmartSpec3000 spectrophotometer (Bio-Rad Laboratories, Hercules, 
CA, USA) at 550 nm with a kinetic program with 15 s intervals over a 3 min period.  The 
ΔO.D. was used for CO activity calculation with an extinction coefficient of 19000/M-
cm.  Each sample solution was read in triplicate and each homogenate was reacted 5 
times.  A measured mean activity of 30.02 mmol/min/g of tissue was used for subsequent 
densitometric analyses. 
 
 
3.2.8.5 CO Densitometric Analysis 
 
Microscope slides were scanned with a Polaroid SprintScan 4000 (Polaroid 
Corporation, Waltham, MA, USA) and PathScan Enabler (Meyer Instrument, Houston, 
TX, USA) at a resolution of 2000 dpi along with brain-paste standards. The digital 
images were imported into ImageJ for densitometry analysis, and the standards were used 
to convert O.D. levels into enzyme activity values, reported as μmol/min/g of tissue for 
each ROI.  Due to considerable variations in raw ROI CO activity, CO activity within 
each ROI was converted to Z-scores for subsequent statistical analysis.   
 
 
3.2.9 Statistical Analyses    
 
The results of all locomotor and biochemical experiments were analyzed by 
means of one-way ANOVA using SAS.  An alpha (α) of 0.05 was chosen for statistical 
significance.   
 
The results of 2-DG and CO histochemistry were analyzed with unpaired t-tests. 
Data from hMT1 mice were compared to pooled data from hWT and WT mice, given that 
(1) hWT mice express very low levels of human wild-type torsinA (data shown below), 
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and (2) the high correlation of the data generated from hWT and WT mice (Pearson r = 
0.98 for GU; Pearson r = 0.96 for CO activity).  Because of the large number of 
comparisons used in these experiments, the level of significance was set at 0.01 instead of 
0.05.  To evaluate networks altered by mutant torsinA, Pearson correlations were 
calcuated for GU and CO activity in neuroanatomically-connected brain regions.  The 
ratios of CO activities and 2-DG signal densities were analyzed with unpaired t-tests. 
 
 
3.3 RESULTS 
 
 
3.3.1 TorsinA Expression in DYT1 Transgenic Mice 
 
The transgenic expression of human torsinA was confirmed with Northern blot 
analyses.  As shown above in Figure 3-1C, human torsinA transcript appears as a 1.5 kb 
band in transgenic mice and a 2.5 kb fragment in human brain.  The expression of human 
torsinA was robust in hMT1 mice, but was weak in hWT and hMT2 mice.  
 
To extend the Northern blot results, QRT-PCR was performed with total RNA 
from whole brain and striatum, along with species-specific primers and probes.  
Cyclophilin D was used as an endogenous control.  The amplification efficiencies of 
human torsinA (1.99), mouse torsinA (1.98), human cyclophilin D (1.98) and mouse 
cyclophilin D (1.97) were nearly identical.  
 
The whole brain expression of human torsinA was measured in all three 
transgenic lines relative to pooled human whole brain reference RNA, whereas 
expression of human torsinA in the mouse striatum was referenced to RNA obtained 
from a single human striatum.  As shown in Table 3-2, hMT1 mice showed robust 
whole-brain and striatal expression of human torsinA transcript (3.90X or 390% in the 
whole brain and 4.95X or 495% in striatum).  In contrast, hWT and hMT2 mice 
expressed relatively low levels of human torsinA transcript.  Due to the high level of 
human mutant torsinA expression in hMT1 transgenic mice and the low level of mutant 
torsinA expression in hMT2 mice, behavioral, morphological, neurochemical, and 
metabolic studies were limited to the hMT1 transgenic line.   
 
The relative expression of endogenous mouse torsinA transcript was calculated 
for the three transgenic lines.  Analysis of Table 3-2 indicated that the directions of 
change in relative expression were the same for whole brain and striatum.  In whole 
brain, there were neither overall nor individual effects of genotype on relative levels of 
mouse torsinA transcript.  In striatum, although the effect of genotype on endogenous 
torsinA expression was not significant (F3, 27 = 2.09, P = 0.130), individual comparisons 
revealed a significant difference between endogenous torsinA expression in hWT and 
hMT1 mice (F1, 27 = 6.21, P = 0.05).  
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Table 3-2.  Relative levels of human and mouse torsinA transcripts in DYT1 
transgenic mice. 
 
 
Whole Brain RNA 
 
Striatal RNA 
Line Human 
torsinA 
transcript* 
Mouse torsinA 
transcript 
Human 
torsinA  
transcript** 
Mouse torsinA 
transcript 
hMT1 3.90 ± 0.451 
 
1.14 ± 0.14 
 
4.95 ± 0.34 
 
1.33 ± 0.22 
 
hMT2 0.07 ± 0.002 
 
1.01 ± 0.02 
 
0.07 ± 0.02 
 
1.04 ± 0.06 
 
hWT 0.04 ± 0.001 
 
0.95 ± 0.07 
 
0.05 ± 0.03 
 
0.90 ± 0.05 
 
 
WT littermates 
 
-- 1.01 ± 0.02 -- 1.07 ± 0.04 
 
Notes: *Relative to pooled RNA from 23 human brains.  **Relative to striatal RNA from 
a single human brain. 
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3.3.2 Motor Dysfunction in DYT1 Transgenic Mice 
 
The motoric abilities of transgenic mice were evaluated with a battery of tests that 
included the raised-beam task, vertical-rope climbing, footprint analysis, and an 
accelerating rotarod.  In addition, we examined the response of transgenic mice to tail 
suspension.  In aggregate, these tests assessed several overlapping aspects of 
sensorimotor function such as motor power, coordination, and postural stability.   
 
There was no clear-cut evidence of dystonia in any of the mice.  WT, hWT, and 
hMT1 mice did not differ in their response to tail suspension.  In particular, no mice 
exhibited forepaw or hindpaw clasping within the 1-min period of observation.  There 
were no effects of genotype on either the accelerating rotarod (Figure 3-2A and B) or 
vertical rope climbing (Figure 3-2C).  However, there were significant effects of 
genotype on footprint analysis and the raised-beam task (P < 0.05, for both).  Compared 
to WT and hWT mice, hMT1 showed increased hind-base width on footprint analysis (F1, 
76 = 5.21, P = 0.025, Figure 3-2D) and prolonged traversal times on the 12-mm square 
raised-beam task (F1, 53 = 18.85, P < 0.0001, Figure 3-2E).  In follow-up raised-beam 
task experiments, the effect of genotype on the 12-mm and 8-mm round-beam tasks was 
significant for traversal times (F2, 37 = 5.62, P = 0.007; and F2, 37 = 3.52, P = 0.040; 
respectively) and slip counts (F2, 37 = 3.55, P = 0.039; and F2, 37 = 5.45, P = 0.008; 
respectively).  Compared to WT mice, hMT1 mice demonstrated a 24% increase in 
traversal times and a 425% increase in slip counts on the 12-mm round-beam task (P < 
0.05, for both).  As shown in Figure 3-2E and 3-2F, a 29% increase in traversal times 
along with a 650% increase in slip counts were noted on the 8-mm round-beam task (P < 
0.05, for both).  The hWT mice also exhibited prolonged traversal times and more slips 
on the round-beam tasks (P < 0.05, for all). 
 
 
3.3.3 No Cytoplasmic Inclusion Bodies and Nuclear Envelope Vesicles Were 
Found in DYT1 Transgenic Mice 
 
Fluorescent immunocytochemistry was performed to search for ubiquitin- and/or 
torsinA-positive cytoplasmic inclusion bodies in hMT1 mice.  Although all brain regions 
were surveyed, particular attention was focused on the pontine nuclei, cerebral cortex, 
striatum, SNpc, and midbrain.  The relative distribution of torsinA- and ubiquitin-IR did 
not differ between hMT1 and WT mice (Figure 3-3).  TorsinA- and ubiquitin-IR were 
localized to the cytoplasm of neurons, but did not co-localize to cytoplasmic inclusions.  
The subcellular localization pattern of torsinA-IR in hMT1 mice was similar to WT 
littermates with no evidence of increased torsinA-IR surrounding the nuclear envelope.  
Electron microscopy was used to search for ultrastructural abnormalities of the nuclear 
envelope.  In contrast to several other mouse models of DYT1 dystonia, we were unable 
to identify bleb formation at the nuclear envelope in hMT1 mice (Figure 3-4).   
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Figure 3-2.  Behavioral analysis of motor functioning in DYT1 transgenic mice. 
Performance of WT (filled circles or black bars), hWT (filled inverted triangles or gray 
bars) and hMT1 (filled squares or dark gray bars) mice was quantitative analyzed in an 
accelerating rotarod with increasing destination speeds (A); in an accelerating rotarod 
with the same destination speed for five consecutive days (B); in vertical-rope climbing 
(C); footprint analysis (D); and the raised beam task with 12-mm square-beam, 12-mm 
round-beam, and 8-mm round-beam (E, F).  Results are expressed as the mean ± SEM.  * 
denotes a significant difference between hMT1 and WT littermates (p < 0.05).  + denotes 
a significant difference between hMT1 and hWT littermates (p < 0.05).  ** denotes a 
significant difference between hWT and WT littermates (p < 0.05). 
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Figure 3-3.  Cellular localization of torsinA and ubiquitin immunoreactivity in 
neurons. 
High-magnification confocal images of double-label fluorescent immunocytochemistry 
for simultaneous detection of torsinA (green, right column gray scale) and ubiquitin (red, 
middle column gray scale) in the pontine nuclei of hMT1, hWT and WT mice.  No 
obvious torsinA and ubiquitin-IR cytoplasmic inclusions or increased torsinA-IR in 
nuclear envelope was found in hMT1.  Double-label cells appear yellow in the merged 
images.  Scale bar, 25 µm.
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Figure 3-4.  Electron microscopic images of the nuclear envelopes in DYT1 
transgenic mice. 
Electron microscopy was used to identify nuclear envelope blebs in the pontine nuclei, 
cerebellum, spinal cord, and striatum of hMT1, hWT, and WT mice.  There was no 
nuclear envelope blebs (arrow) found in these regions.  Scale bar, 1μm.
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3.3.4 Neurochemical Phenotype of DYT1 Transgenic Mice 
 
In order to examine the possibility of a neurochemical imbalance in ΔGAG DYT1 
transgenic mice, HPLC-EC was performed to quantify levels of monoamines and their 
metabolites in striatum, cerebellum, and cerebral cortex.  As seen in Figure 3-5, there 
was a noteworthy effect of genotype on the level of DOPAC (F2, 28 = 4.89, P = 0.015) in 
the cerebellum. Compared to WT mice, DOPAC was 59% higher (P = 0.026) in hMT1 
mice.  In cerebral cortex, a significant effect of genotype was apparent with respect to 5-
HT (F2, 28 = 3.87, P = 0.033).  Compared to WT mice, 5-HT content was 98% higher (P 
= 0.012) in hWT mice.  Similarly, 5-HT content also tended to be higher in hMT1 than in 
WT mice (76%, P = 0.054).  In the striatum, significant effects of genotype were 
observed for EPI (F2, 28 = 3.45, P = 0.046), DOPAC (F2, 28 = 4.99, P = 0.014), and 
HVA (F2, 28 = 5.26, P = 0.012) levels.  In comparison to WT mice, EPI, DOPAC, and 
HVA levels were increased by 85% (P = 0.016), 58% (P = 0.004) and 76% (P = 0.007), 
respectively, in hMT1 mice.  Although there was no significant difference in striatal DA 
content between hMT1 and WT mice, DA turnover (DOPAC/DA and HVA/DA) was 
significantly higher in the mutants (P = 0.006 or both; Figure 3-6).  To note, a significant 
elevated level of DOPAC was also found in the cerebellum in hWT mice (P = 0.006). 
 
 
3.3.5 Brain Metabolic Abnormalities in DYT1 Transgenic Mice 
 
2-DG autoradiography as well as CO histochemistry was used to map brain 
metabolic activity in hMT1, hWT, and WT mice.  2-DG autoradiography and CO 
histochemistry provide complementary information regarding the glycolytic and 
oxidative metabolism of the brain, in general.  CO histochemistry is more specific for 
neuronal activity, and readily demarcates the boundaries of neural structures.  
Cytochrome c-oxidase (i.e., CO) is the terminal enzyme complex in the electron transport 
chain of mitochondria.  The regulation and assembly of CO requires a coordinated 
interaction of the nuclear and mitochondrial genomes (Fontanesi et al., 2006).  CO is 
more specific for oxidative metabolism and more reflective of neuronal metabolic 
demands that occurr over days to weeks (Di Rocco et al., 1989; Wong-Riley, 1989; 
Gonzalez-Lima and Garrosa, 1991; Hevner et al., 1995).  However, 2-DG is a glucose 
analogue that has the 2-hydroxyl group replaced by a hydrogen so that it cannot undergo 
glycolysis.  Glucose hexokinase trapped 2-DG in most cells, which can be used as a good 
marker for immediate tissue demand for glucose and its signal reflects both synaptic.and 
neural activities (Wree and Schleicher, 1988; Wree, 1990; Duncan and Stumpf, 1991; 
McCasland and Graczyk, 2001).  In addition, the spatial resolution of CO histochemistry 
is superior to 2-DG autoradiography. 
 
 
3.3.5.1 CO Activity in DYT1 Transgenic Mice 
 
The regional distribution of CO staining observed in WT mouse brain was similar 
to the pattern that described for rat brain (Hevner et al., 1995).  The highest densities of 
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Figure 3-5.  Quantitative HPLC-EC analysis of monoamines and their metabolites 
in DYT1 transgenic mice. 
Striatal, cerebral cortical, and cerebellar monoamines and their metabolites were analysed 
in WT (black bars), hWT (gray bars), and hMT1 (dark gray bars) mice.  DOPAC level 
increase was observed in striatum and cerebellum of hMT1.  Similarlly, HVA and EPI 
level increases in hMT1 were observed in striatum.  Results are expressed as the mean ± 
SEM.  * denotes a significant difference between hMT1 and WT littermates (P < 0.05).  
+ denotes a significant difference between hMT1 and hWT littermates (P < 0.05).  ** 
denotes a significant difference between hWT and WT littermates (P < 0.05).
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Figure 3-6.  Dopamine turnover in the striatum of DYT1 transgenic mice. 
Dopamine turnover of WT (black bars), hWT (gray bars), and hMT1 (dark gray bars) 
mice was expressed as DOPAC/DA and HVA/DA ratios.  Striatal DOPAC/DA and 
HVA/DA were significantly increased in hMT1.  Results are expressed as the mean ± 
SEM.  * denotes a significant difference between hMT1 and WT littermates (P < 0.05).  
+ denotes a significant difference between hMT1 and hWT littermates (P < 0.05). 
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CO histochemical staining was found in cerebellar cortex, deep cerebellar nuclei, red 
nucleus, caudate-putamen, subthalamic nucleus, and subregions of the cerebral cortex. 
The lowest levels of CO histochemical staining were found in white matter (e.g., corpus 
callosum) and neuronal populations with intermingled fiber pathways (e.g., globus 
pallidus).  In gray matter, the density of CO staining was not correlated with neuronal 
density.  For example, regions with dense neuronal packing such as the substantia nigra 
pars compacta and granule cell layer of the dentate gyrus were weakly visualized with 
CO histochemistry.  Furthermore, compatible with the density of mitochondria at 
synapses, some regions with a relative paucity of neuronal soma such as the molecular 
layer in cerebellar cortex and stratum lacunosum-moleculare in hippocampus, showed a 
relatively high CO staining.  In some regions, the cellular patterns of CO staining were 
quite distinctive.  For example, in the red and vestibular nuclei, the majority of CO 
staining was noted in the somas, whereas in the caudate-putamen and deep cerebellar 
nuclei, neuronal soma and contiguous neuropil stained with similar intensity.   
 
Densitometric analysis of CO activity in 55 neuroanatomical ROIs did not 
identify a difference in whole brain CO activity between hMT1 and control mice. 
However, after converting ROI CO activity to Z-scores, significant alterations in CO 
activity were noted in individual neural structures.  As seen in Table 3-3, significant 
increases of CO activity were found in the inferior olive medial nucleus (IOM) and 
Purkinje cell layer of cerebellar cortex in hMT1 mice in comparison with controls 
,whereas significant decreases of CO activity were found in hMT1 caudal caudate-
putamen, substantia nigra pars reticulata and somatosensory 1 hindlimb in comparison 
with controls.   
 
 
3.3.5.2 GU in ROIs in DYT1 Transgenic Mice 
 
Aggregate densitometric analysis of the 40 neuroanatomical ROIs showed that 
whole-brain GU was similar between hMT1 and control mice.  However, comparison of 
individual ROI GU Z-scores revealed a significantly altered GU in several motor regions 
of the brain.  Z-scores of GU in the 40 ROIs and the respective statistical values are 
presented in Table 3-4.  In comparison to controls, hMT1 mice showed a significantly 
increased GU in IOM, inferior olive dorsal accessory nucleus (IOD), and SNpc and a 
significant reduced GU in medial globus pallidus (MGP) and lateral globus pallidus 
(LGP).   
 
 
3.3.5.3 Correlation Analysis 
 
To provide additional interrogation of regional metabolic demand in the 
sensorimotor regions of the brain (e.g., basal ganglia, cerebellum, and their input and 
output nuclei), the correlation coefficients between anatomically-connected ROIs were 
analyzed with Z-scores derived from CO histochemistry.  Significant positive 
correlations were noted between the interposed and red nuclei (0.54), medial cerebellar 
and red nuclei (0.67), rostral caudate-putamen and LGP (0.74), rostral caudate-putamen  
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Table 3-3.  CO activity distribution in ROIs in DYT1 transgenic mice. 
 
CO activity (μmol/min/g) Z-score ROI P (Z-score) Control hMT1 Control hMT1 
CPuC 0.0007 41.43 ± 1.92 39.98 ± 2.64 1.47 ± 0.09 0.93 ± 0.1 
SNR 0.0033 24.61 ± 1.69 25.86 ± 2.06 -0.63 ± 0.05 -0.85 ± 0.05 
IOM 0.0062 20.15 ± 2.54 28.85 ± 2.17 -1.14 ± 0.18 -0.45 ± 0.15 
PCL 0.0077 35.53 ± 2.16 44.04 ± 2.94 0.74 ± 0.11 1.45 ± 0.2 
S1HL 0.0099 35.19 ± 1.96 34.57 ± 2.57 0.67 ± 0.08 0.26 ± 0.11 
GL 0.0110 27.26 ± 1.78 33.32 ± 2.49 -0.28 ± 0.09 0.11 ± 0.11 
VLG 0.0125 28.7 ± 2.16 28.43 ± 2.12 -0.12 ± 0.07 -0.5 ± 0.11 
MGP 0.0141 15.83 ± 1.07 16.09 ± 1.34 -1.72 ± 0.1 -2.06 ± 0.08 
ML 0.0172 31.17 ± 2.08 38.71 ± 2.67 0.19 ± 0.1 0.77 ± 0.19 
S1FL 0.0234 34.94 ± 1.81 34.67 ± 2.54 0.66 ± 0.07 0.28 ± 0.13 
IOD 0.0299 19.77 ± 1.74 27.49 ± 2.16 -1.18 ± 0.11 -0.6 ± 0.21 
Lat 0.0385 35.38 ± 2.96 43.32 ± 3.69 0.73 ± 0.19 1.3 ± 0.18 
Po 0.0601 31.92 ± 2.08 32.45 ± 3.1 0.27 ± 0.09 -0.06 ± 0.13 
CPuRV 0.0765 41.33 ± 1.94 40.97 ± 2.95 1.45 ± 0.15 1.04 ± 0.16 
Rt 0.0783 25.61 ± 1.64 26.05 ± 2.35 -0.51 ± 0.07 -0.83 ± 0.15 
AInt 0.0838 33.51 ± 2.7 40.4 ± 3.86 0.5 ± 0.17 0.92 ± 0.16 
CPuRD 0.0917 31.48 ± 1.59 31.85 ± 2.42 0.22 ± 0.14 -0.09 ± 0.11 
Med 0.0951 21.67 ± 2.07 27.99 ± 2.8 -0.95 ± 0.12 -0.62 ± 0.14 
BLA 0.1585 33.93 ± 1.83 34.67 ± 3.08 0.53 ± 0.11 0.25 ± 0.15 
DC 0.1633 26.33 ± 3.05 34.94 ± 4.26 -0.35 ± 0.24 0.25 ± 0.33 
LGP 0.1671 23.86 ± 1.42 25.14 ± 2.09 -0.72 ± 0.09 -0.94 ± 0.12 
Cg 0.1951 33.9 ± 2.05 34.32 ± 2.64 0.53 ± 0.13 0.24 ± 0.17 
S1BF 0.2564 33.93 ± 1.82 36.64 ± 3.02 0.64 ± 0.11 0.49 ± 0.06 
CA3poly 0.2760 29.13 ± 1.93 30.79 ± 3.05 -0.08 ± 0.1 -0.24 ± 0.11 
IPC 0.3013 28.46 ± 2.33 34.19 ± 2.62 -0.07 ± 0.17 0.21 ± 0.2 
M2 0.3666 31.66 ± 1.61 32.39 ± 2.4 0.37 ± 0.12 0.17 ± 0.17 
VP 0.3696 34.64 ± 1.98 38.59 ± 3.19 0.63 ± 0.08 0.74 ± 0.09 
LVe 0.4113 20.38 ± 2.33 25.22 ± 2.2 -1.1 ± 0.14 -0.93 ± 0.14 
M1 0.4250 34.13 ± 1.64 35.08 ± 2.86 0.69 ± 0.14 0.49 ± 0.19 
Pn 0.4540 15.33 ± 2.06 16.81 ± 1.98 -1.74 ± 0.12 -1.95 ± 0.23 
VL 0.4967 24.91 ± 1.95 27.68 ± 2.45 -0.6 ± 0.1 -0.49 ± 0.11 
S2 0.4974 30.23 ± 1.65 33.04 ± 2.63 0.18 ± 0.13 0.05 ± 0.13 
SO 0.5624 28.71 ± 1.99 30.66 ± 2.86 -0.14 ± 0.11 -0.24 ± 0.15 
SR 0.5775 26.15 ± 1.95 28.01 ± 2.61 -0.46 ± 0.13 -0.57 ± 0.15 
LSO 0.5816 30.4 ± 2.66 35.61 ± 3.47 0.18 ± 0.2 0.38 ± 0.28 
VM 0.6569 26.65 ± 2.11 28.01 ± 2.34 -0.39 ± 0.1 -0.43 ± 0.04 
CIC 0.6717 39.22 ± 2.93 43.94 ± 4.21 1.23 ± 0.25 1.38 ± 0.26 
MG 0.6852 30.79 ± 2.1 33.44 ± 2.72 0.15 ± 0.12 0.09 ± 0.1 
PAG 0.6866 24.6 ± 1.93 27.39 ± 2.29 -0.61 ± 0.08 -0.66 ± 0.08 
MVe 0.7003 23.84 ± 3.29 26.68 ± 4.56 -0.66 ± 0.25 -0.82 ± 0.34 
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Table 3-3.  (Continued). 
 
CO activity (μmol/min/g) Z-score ROI P (Z-score) Control hMT1 Control hMT1 
H 0.7014 23.76 ± 1.77 26.18 ± 2.83 -0.74 ± 0.1 -0.81 ± 0.14 
PnO 0.7136 23.93 ± 2.01 27.42 ± 2.17 -0.71 ± 0.08 -0.66 ± 0.1 
InG 0.7151 30.84 ± 2.2 33.11 ± 3.04 0.14 ± 0.1 0.06 ± 0.18 
LD 0.7523 29.4 ± 2.45 31.91 ± 2.75 -0.04 ± 0.1 -0.09 ± 0.13 
oDG 0.7837 27.46 ± 2.26 30.07 ± 2.47 -0.26 ± 0.12 -0.31 ± 0.09 
RMC 0.8130 37.59 ± 1.91 41.37 ± 2.91 1.04 ± 0.19 1.13 ± 0.33 
STh 0.8254 45.46 ± 2.83 48.49 ± 3.17 1.95 ± 0.11 1.99 ± 0.16 
SLM 0.8510 47.88 ± 2.72 50.19 ± 3.61 2.26 ± 0.15 2.22 ± 0.15 
DLG 0.8533 30.58 ± 2.21 33.17 ± 2.62 0.1 ± 0.08 0.08 ± 0.1 
RMg 0.8642 14.08 ± 1.24 17.13 ± 1.98 -1.9 ± 0.1 -1.93 ± 0.12 
VA 0.8840 30.58 ± 2.37 32.15 ± 2.51 0.09 ± 0.1 0.11 ± 0.06 
APTD 0.9249 29.76 ± 2.19 32.6 ± 2.84 -0.01 ± 0.08 0.01 ± 0.14 
LC 0.9434 23.39 ± 2.14 26.58 ± 2.59 -0.78 ± 0.11 -0.77 ± 0.13 
iDG 0.9576 34.61 ± 2.36 37.44 ± 3.33 0.58 ± 0.14 0.59 ± 0.13 
SuG 0.9897 27.45 ± 2.02 30.31 ± 3.11 -0.29 ± 0.13 -0.29 ± 0.2 
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Table 3-4.  GU distribution in ROIs in DYT1 transgenic mice. 
 
GU (nCi/g) Z-score ROI P (Z-score) control hMT1 control hMT1 
MGP 0.0011 164.84 ± 11.91 154.64 ± 12.09 -1.53 ± 0.06 -1.88 ± 0.06 
IOM 0.0018 225.91 ± 13.23 269.48 ± 18.13 -0.59 ± 0.07 -0.22 ± 0.07 
IOD 0.0063 183 ± 13.41 220.78 ± 14.27 -1.26 ± 0.08 -0.93 ± 0.07 
SNpc 0.0077 235.33 ± 14.85 271.21 ± 16.43 -0.46 ± 0.08 -0.2 ± 0.04 
LGP 0.0097 184.25 ± 11.95 182.5 ± 14.19 -1.22 ± 0.06 -1.49 ± 0.07 
VM 0.0226 282.09 ± 16.73 321.88 ± 18 0.26 ± 0.06 0.56 ± 0.1 
IPC 0.0265 305.68 ± 20.73 305.04 ± 20.69 0.61 ± 0.11 0.29 ± 0.07 
STh 0.0430 284.99 ± 16.96 295.72 ± 19.07 0.3 ± 0.05 0.15 ± 0.04 
Lat 0.0745 286.87 ± 16.52 320.02 ± 20.51 0.33 ± 0.08 0.5 ± 0.04 
RMCR 0.0863 283.83 ± 16.57 294.31 ± 21.4 0.28 ± 0.03 0.12 ± 0.08 
CHem 0.1134 224.74 ± 13.66 251.99 ± 16.94 -0.61 ± 0.04 -0.48 ± 0.06 
CVer 0.1158 240.14 ± 12.99 270.75 ± 17.24 -0.37 ± 0.06 -0.21 ± 0.08 
S2 0.1719 269.37 ± 15.03 281.07 ± 16.75 0.08 ± 0.07 -0.05 ± 0.05 
SO 0.1743 350.22 ± 17.8 346.05 ± 18.6 1.32 ± 0.13 0.92 ± 0.24 
Med 0.1972 273.69 ± 15.92 303.08 ± 19.09 0.13 ± 0.09 0.26 ± 0.03 
Cg 0.2290 271.43 ± 15.95 279.64 ± 21.04 0.1 ± 0.11 -0.09 ± 0.11 
PAG 0.2423 150.44 ± 10.3 157.52 ± 13.81 -1.73 ± 0.08 -1.85 ± 0.06 
VL 0.2446 256.73 ± 15.8 286.89 ± 17.51 -0.13 ± 0.08 0.07 ± 0.14 
SuG 0.2881 226.78 ± 17.49 232.41 ± 17.57 -0.61 ± 0.12 -0.76 ± 0.07 
AInt 0.3113 290.78 ± 16.6 320.08 ± 22.12 0.39 ± 0.07 0.49 ± 0.06 
IC 0.3603 500.71 ± 24.13 546.82 ± 41.84 3.56 ± 0.09 3.73 ± 0.15 
M1 0.3666 254.09 ± 14.81 277.18 ± 17.29 -0.17 ± 0.06 -0.1 ± 0.05 
SNR 0.4315 176.44 ± 15.04 183.86 ± 16.81 -1.37 ± 0.09 -1.47 ± 0.09 
Pn 0.4436 178.05 ± 15.44 200.94 ± 18.82 -1.34 ± 0.09 -1.23 ± 0.1 
M2 0.5350 283.14 ± 15.73 300.19 ± 20.64 0.28 ± 0.09 0.21 ± 0.06 
RMCC 0.5357 281.25 ± 17.8 296.72 ± 21.16 0.23 ± 0.07 0.16 ± 0.09 
PnO 0.5581 220.91 ± 17.16 243.15 ± 16.44 -0.68 ± 0.08 -0.61 ± 0.09 
S1BF 0.5738 320.91 ± 16.57 338.78 ± 19.07 0.87 ± 0.08 0.79 ± 0.09 
CPuRV 0.6788 258.39 ± 16.79 271.97 ± 15.75 -0.11 ± 0.1 -0.17 ± 0.1 
LC 0.7010 230.53 ± 14.07 256.78 ± 21.73 -0.5 ± 0.1 -0.43 ± 0.17 
Mve 0.7422 323.03 ± 18.28 349.86 ± 24.12 0.87 ± 0.08 0.93 ± 0.14 
RMg 0.7548 235.12 ± 16.58 250.19 ± 17.96 -0.45 ± 0.12 -0.51 ± 0.13 
VP 0.7591 318.19 ± 17.07 337.13 ± 17.19 0.81 ± 0.08 0.78 ± 0.08 
CPuC 0.8067 251.74 ± 14.78 271.14 ± 14.94 -0.21 ± 0.08 -0.18 ± 0.08 
DC 0.8361 306.96 ± 16.08 325.65 ± 24.74 0.63 ± 0.11 0.58 ± 0.21 
VA 0.9079 339.91 ± 19.22 362.17 ± 17.83 1.13 ± 0.07 1.16 ± 0.16 
S1HL 0.9513 264.41 ± 14.87 285.63 ± 22.4 0 ± 0.09 -0.01 ± 0.09 
CPuRD 0.9768 274.32 ± 14.68 294.23 ± 17.14 0.15 ± 0.09 0.14 ± 0.04 
LVe 0.9897 330.62 ± 19.6 351.85 ± 20.72 0.97 ± 0.07 0.97 ± 0.08 
S1FL 0.9921 267.1 ± 14.73 287.52 ± 18.82 0.04 ± 0.09 0.04 ± 0.07 
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and MGP (0.64), and LGP and MGP (0.77) in control but not hMT1 mice.  In addition, 
significant negative correlations were noted between rostral caudate-putamen and 
subthalamic nucleus (STh; -0.70), and MGP and STh (-0.51) in control but not in hMT1 
mice (Table 3-5).  The loss of correlations indicated the functional abnormalities in these 
pathways in hMT1 mice. 
 
 
3.4 DISCUSSION 
 
Several murine models of DYT1 dystonia have been developed and characterized 
to varying degrees (Dang et al., 2005, Goodchild et al., 2005; Sharma et al., 2005; 
Shashidharan et al., 2005; Dang et al., 2006; Grundmann et al., 2007; Table 1-2).  
Although some common themes exist among these models, substantial discordance has 
been apparent in morphological findings, and robust behavioral and neurochemical 
characterizations have been largely incomplete.  In our study, detailed genetic, 
behavioral, morphological, neurochemical, and brain metabolical analyses were 
performed in a human ΔGAG transgenic mouse model of DYT1 dystonia.  Our results 
demonstrated a high-level mutant transgene expression in hMT1 mice, in addition to 
distinct motor, neurochemical, and brain metabolical abnormalities in the hMT1 line.  
These findings demonstrate that the human mutant torsinA transgenic mouse (hMT1) is a 
valid model for the study of DYT1 dystonia.  Of utmost importance, our results indicate 
that defective nigrostriatal signaling, as demarcated with an increased striatal DA 
turnover might be critical to the pathobiology of DYT1 dystonia.   
 
Transgenic models of DYT1 dystonia have been developed by Sharma et al. 
(2005), Shashidharan et al. (2005), and Grundmann et al. (2007).  Using quantitative 
analysis of Western blots, Sharma and colleagues (2005) showed that hMT1, hMT2, and 
hWT transgenic mice express torsinA at 2.1X, 1.3X, and 2.3X that of WT littermates.  
Similarly, Shashidharan and co-workers (2005) showed an increased torsinA protein 
expression in four transgenic lines (TG#13, TG#22, TG#35, and TG#49).  In more recent 
work, Grundmann and colleagues (2007) analyzed normal and mutant human torsinA 
transgene expression at the transcript and protein levels.  Human torsinA transcript levels 
were referenced to the hWT24 line of mice.  The largest fold increase in transcript levels 
was noted in the hΔGAG3 line of torsinA mutant mice (1.30X). In a more functional 
assay, we showed that striatal torsinA transcript expression was 3.90X higher in hMT1 
mice than in human brain.  Because current thinking indicates that a single mutant 
torsinA molecule can disrupt assembly of a mature hexameric molecular motor 
(Breakefield et al. 2001), stoichiometric considerations would suggest that an increase in 
the cellular burden of mutant torsinA would decrease the probability of hexamer 
formation.  Apparently, a minimal number of functional torsinA hexamers are required 
for normal neural function and organismal survival because DYT1 knockout and 
homozygous DYT1 knock-in mice die shortly after birth (Goodchild et al. 2005).  
Therefore, robust transgenic expression of mutant torsinA as seen in hMT1 mice might 
be the most viable means to model human DYT1 dystonia.  
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Table 3-5.  Pearson correlations between neuroanatomically-connected nuclei in DYT1 transgenic mice. 
 
CO Activity 2-DG Autoradiography 
Control hMT1 Control hMT1 ROI 
r P (r) r P (r) 
P 
(Ratio) r P (r) r P (r) 
P 
(Ratio) 
AInt / RMC 0.54 0.0264 -0.01 0.9818 0.2335 0.22 0.4503 0.48 0.2312 0.0412 
Med / RMC 0.67 0.0036 -0.51 0.1574 0.1151 0.21 0.4802 0.38 0.3522 0.0298 
RVCPu / LGP 0.74 0.0007 0.56 0.117 0.1579 0.22 0.45 -0.03 0.944 0.1676 
RVCPu / MGP 0.64 0.0061 0.44 0.234 0.5142 0.06 0.8348 -0.67 0.0703 0.0867 
RVCPu / STh -0.7 0.0017 0.28 0.463 0.1109 -0.47 0.0934 -0.77 0.0244 0.6592 
RDCPu / LGP 0.83 <0.0001 0.36 0.3401 0.4022 0.25 0.3888 -0.05 0.9054 0.0593 
RDCPu / MGP 0.79 0.0001 0.48 0.1899 0.6819 0.04 0.8863 -0.49 0.2181 0.0257 
RDCPu / STh -0.7 0.0016 -0.13 0.7389 0.2526 -0.6 0.0232 -0.63 0.0937 0.6592 
CCPu / LGP 0.72 0.0012 0.84 0.0044 0.0213 0.19 0.5075 -0.79 0.0189 0.1038 
CCPu / MGP 0.5 0.0399 0.69 0.0395 0.2707 0.13 0.6525 -0.39 0.3446 0.0264 
LGP / MGP 0.77 0.0003 0.63 0.0668 0.5528 0.49 0.0738 0.39 0.3338 0.2189 
MGP / STh -0.51 0.0364 0.4 0.2918 0.3354 0.03 0.9187 0.46 0.2481 0.0211 
Lat / IOM 0.59 0.0134 0.13 0.7463 0.0243 0.1 0.7258 0.32 0.4358 0.0406 
 
Notes: r, pearson correlation coefficient; P (r), significant value for the correlation coefficient; P (Ratio), significant value for 
the ratios between the two groups.
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Genetically engineered mice cannot accurately model all of the molecular, 
cellular, and physiological features of human neurogenetic disorders.  Individual models 
have their own distinct limitations and utilities.  In transgenic models, the promoter, 
construct design and insertion site dictate the temporal and spatial regulation of transgene 
expression.  Moreover, transgenic models might be associated with locus-specific 
insertional effects.  In a comparative analysis of torsinA transgenic models, several points 
must be considered.  First, utilization of a neuron-specific promoter like neuron-specific 
enolase precludes consideration of glial-specific and glial-neuronal interactions as 
contributors to the pathophysiology of DYT1 dystonia (Shashidharan et al., 2005).  
Furthermore, the mice generated by Shashidharan and colleagues (2005) exhibited 
bizarre circling behavior that is not seen in other murine models of DYT1 dystonia.  In 
the transgenic mice generated by Grundmann et al. (2007), the expression of mutant 
torsinA that contained a V5-his tag was driven by the murine prion protein promoter 
(Grundmann et al., 2007).  It is possible that even a small V5-his tag could interfere with 
one or more functional properties of torsinA.  In contrast to other transgenic models of 
DYT1 dystonia, the expression of untagged mutant torsinA in hMT1 mice is driven by 
the cytomegalovirus (CMV) promoter, which is well-known for its ability to drive 
widespread transgene expression (Boshart et al., 1985; Sharma et al., 2005). 
 
Similar to other models of DYT1 dystonia, none of the transgenic mice used in 
our study (hMT1, hMT2, and hWT) showed overt evidence of dystonia.  The response of 
hMT1 mice to tail suspension and performance on vertical-rope climbing and the 
accelerating rotarod were all similar to WT littermates.  However, hMT1 mice exhibited 
a mildly abnormal motor phenotype characterized by an increased hind-base width and an 
impaired performance on the raised-beam task.  These findings are consistent with 
previous reports of heterozygous DYT1 knock-in and DYT1 knock-down mice (Dang et 
al., 2005; 2006), as well as hWT24 transgenic mice (Grundmann et al., 2007).  DYT1 
knock-in mice display an abnormal gait with a significant overlap in paw placement, as 
well as motor coordination deficits on the raised-beam task (Dang et al., 2005).  DYT1 
knock-down mice also demonstrated motor-coordination deficits on the raised-beam task 
(Dang et al., 2006).  The raised-beam task integrates multiple components of the 
sensorimotor system, and has been used for functional evaluation of the nigrostriatal 
pathway (Dluzen et al., 2001) and to estimate the deficits induced by sensorimotor cortex 
ablation (Goldstein & Davis, 1990) and ischemic stroke (Brown et al., 2004).  The raised-
beam task has also been used to characterize motor dysfunction in murine models of 
"basal ganglia" disorders such as Huntington and Parkinson diseases (Carter et al., 1999; 
Strome et al., 2006).  Because abnormalities in dopaminergic neurotransmission in mice 
have been associated with hypoactivity, stride-length reduction, and poor performance on 
the raised-beam task, an explanation for the motor abnormalities of hMT1 transgenic 
mice might be derived, in part, from the observed increase in striatal DA turnover 
(Dluzen et al. 2001; Fernagut et al. 2002; 2003).  
 
Footprint analysis is another useful tool used to evaluate motor and gait 
abnormalities in murine models of movement disorders.  Footprint analysis along with 
digital surrogates have been used to examine gait alterations induced by striatal damage 
(Teunissen et al., 2001), genetic defects of Purkinje cells (Jiao et al., 2005), sensory 
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neuropathy (Wietholter et al., 1990), and diffuse cerebral disease (McGavern et al., 
1999).  As is the case for human gait disorders, distinct footprint patterns can be ascribed 
to lesions of specific neural subsystems in mice. Animals with cerebellar defects, for 
instance, often display considerable increases in front- and hind-base widths (Wietholter 
et al., 1990; Jiao et al., 2005).  In agreement with functional-imaging studies, the 
increased hind-base width noted in hMT1 mice suggested that mutant torsinA might 
contribute to cerebellar dysfunction in humans with DYT1 dystonia (Carbon et al., 
2004a).   
 
Work in Drosophila suggests that torsinA could play a role at the mammalian 
neuromuscular junction (Koh et al., 2004).  In our study, the performance of torsinA 
mutant mice on vertical-rope climbing does not entirely dismiss this possibility because 
hMT1 mice tended to perform worse than WT littermates.  Vertical-rope climbing 
requires substantial motor strength, and is likely to illicit abnormalities in mice with 
disorders of muscle, the neuromuscular junction, or anterior horn cells (Anderson et al., 
2005). 
 
Unlike two previous studies with torsinA transgenic mice, we were unable to 
identify rotarod abnormalities in either hMT1 or hWT mice (see Table 1-2).  In this 
regard, several points are worthy of note.  First, Grundmann et al. (2007) employed 6-
month old mice and Sharma and colleagues (2005) only found rotarod abnormalities in 
mice at 9 months of age.  In contrast, our studies were performed in much younger adult 
mice.  Second, Sharma et al. (2005) pooled results from hMT1 and hMT2 mice, whereas 
we restricted our behavioral experiments to hMT1 mice.  Finally, all of our experiments 
were performed with mice backcrossed (C57BL/6J) at least 8 generations, whereas 
Sharma et al. (2005) combined F5 and F6 progeny for their experiments.  Grundmann et 
al. (2007) did not comment on the genetic uniformity of their mice.  In this context, it 
should be emphasized that our hWT mice are not a viable model of human wild-type 
torsinA overexpression.  Similarly, with regards to the hMT2 mice, it is likely that mutant 
transgene expression is too low to significantly disrupt cellular pathways that are 
dependent on torsinA.  It is possible that transgene repression or inactivation, which has 
been described in numerous plant and animal models, is responsible for the Northern blot 
and QRT-PCR results seen in hWT and hMT2 mice (Kilby et al., 1992; Chevalier-
Mariette et al., 2003; Thomas et al. 2005).  DNA methylation, which might occur over 
several generations, appears to be the most common mechanism of transgene 
repression/inactivation.    
 
Although to a lesser degree than the hMT1 mice, the hWT line of mice also 
exhibited prolonged traversal times and more slips on the round raised-beam tasks.  
These abnormalities in the hWT mice might be an insertional effect of the transgene since 
expression of the wild-type torsinA was negligible in these mice.  Alternatively, a 
deleterious effect of small amounts of wild-type human torsinA cannot be excluded since 
Grundmann and colleagues also noted behavior abnormalities in mice expressing wild-
type human torsinA (Grundmann et al., 2007).   
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Laser-scanning confocal and electron microscopy were used to search for cellular 
and ultrastructural abnormalities in torsinA transgenic mice.  Our results are compatible 
with the initial report of Sharma and colleagues (2005), but differ from findings in other 
DYT1 transgenic, knock-in, and knock-out models. (Shashidharan et al., 2005; Dang et 
al., 2005; Goodchild et al., 2005; Grundmann et al., 2007).  Morphological analysis of 
other DYT1 models has revealed ubiquitin- and torsinA-positive cytoplasmic inclusion 
bodies (Shashidharan et al., 2005; Dang et al., 2005; Grundmann et al., 2007), as well as 
bleb formation at the nuclear envelope (Goodchild et al., 2005; Grundmann et al., 2007; 
Table 1-2).  It is likely that technical factors related to tissue processing, rodent age, and 
relative cytoplasmic concentration of endogenous torsinA contributed to the appearance 
of cytoplasmic inclusions and nuclear envelope bleb formation.  Because DYT1 dystonia 
rarely appears after 28 years of age, we chose to use young adult mice for our studies.  
Because inclusion formation in most neurodegenerative diseases is closely tied to the 
aging process, our failure to detect cytoplasmic inclusions in young adult mice is not 
surprising.  With regard to nuclear envelope bleb formation, it should be emphasized that 
our mice were perfused with a fixative (4% paraformaldehyde/2.5% glutaraldehyde/15% 
picric acid), which is well-known to preserve ultrastructural morphology.  Marked 
reduction in functional torsinA is also required for the appearance of nuclear envelope 
blebs because structural abnormalities of the nuclear envelope were described in 
homozygous DYT1 knock-in and knock-out mice, but not in their heterozygote DYT1 
littermates (Goodchild et al., 2005).  In aggregate, motor and neurochemical 
abnormalities were observed in DYT1 models that demonstrated cellular pathology, as 
well as in those that do not.  Thus, causal relationships among morphological, motor, and 
neurochemical phenotypes remain unclear.  
 
To investigate the possibility of a neurochemical abnormality in torsinA mutant 
mice, we performed HPLC-EC analysis of monoamine transmitters and their metabolites.  
The most striking findings were significantly increased DOPAC/DA and HVA/DA ratios 
(measures of DA turnover) in hMT1 striatum.  Increases in DOPAC/DA and HVA/DA 
turnover can manifest from a number of scenarios, including an increased DA release, a 
decreased DA uptake due to abnormal functioning of the dopamine and/or vesicular 
monoamine transporters, or an increased monoamine oxidase (MAO) activity.  Our 
findings in DYT1 transgenic mice are compatible with previous neuroimaging and 
postmortem neurochemical studies of human DYT1 dystonia.  For example, Augood and 
colleagues (2002) observed a significantly increased DOPAC/ DA ratio, along with a 
trend toward reduction in D1 and D2 receptor binding in the striatum of human 
postmortem DYT1 dystonia brains.  A corresponding decrease in striatal D2 receptor 
binding has been described in non-manifesting DYT1 mutation carriers (Asanuma et al., 
2005).  Increased striatal DA turnover and down-regulation of striatal D2 receptors 
suggests that functional and/or morphological anomalies of the nigrostriatal pathway 
might be important to the pathobiology of DYT1 dystonia.   
 
Quite variable results have been reported from the neurochemical analyses of 
other DYT1 mouse models (Table 1-2).  In transgenic mice generated by Shashidharan 
and colleagues (2005), decreased striatal DA levels were observed in mice with motor 
abnormalities (i.e., “affected” mice), whereas increased striatal DA levels were detected 
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in mice without motor abnormalities (i.e., “unaffected” mice).  Despite these differences 
in absolute DA levels, DOPAC/DA ratios were decreased in “affected” and “unaffected” 
mice compared to wild-type controls; those data suggested an overall decrease in DA 
turnover (Shashidharan et al., 2005).  In heterozygote DYT1 knock-in mice, striatal HVA 
levels were found to be significantly decreased with no alterations of DA and DOPAC 
content (Dang et al., 2005), and  DYT1 knock-down mice demonstrated significantly 
reduced DOPAC levels, with only a slight decrease in striatal DA (Dang et al. 2006).  In 
addition to decreased striatal DA, decreases in 5-HT and 5-HIAA were also noted in the 
hWT transgenic mice generated by Grundmann and colleagues (2007).  In the brainstem 
only, a decrease in HVA levels and an increase in DOPAC, 5-HT and 5-HIAA levels 
were noted in hΔGAG3 transgenic mice (Grundmann et al., 2007).  Taken together, these 
mixed neurochemical findings in DYT1 mouse models suggest that mutant and WT 
torsinA can both influence striatal dopaminergic neurotransmission.  
 
GU and CO activity serve as surrogate and indirect markers of acute and chronic 
metabolic activities in the brain.   The systems-level information derived from metabolic 
mapping can be integrated with behavioral, neurochemical, and electrophysiological 
alterations in DYT1 mice.  For comparisons with hMT1 mice, the control group included 
data from WT and hWT mice because hWT show negligible transgene expression, and 
ROI GU and CO activity from hWT and WT were highly correlated.  CO activity was 
significantly increased in the IOM and Purkinje cell layer of cerebellar cortex and 
decreased in caudal caudate-putamen, SNR, and S1HL of hMT1 mice in comparison to 
the control group.  Similarly, GU was significantly increased in IOM, IOD, and SNC, and 
was decreased in MGP and LGP in hMT1 mice.   
 
Given that GU and CO activity measure distinct metabolic processes on different 
time scales, it is not surprising that these two metabolic mapping methods generated both 
overlapping and unique results.  Similar inconsistencies between GU and CO metabolic 
patterns have also been reported in the mutant dystonic hamster (Nobrega et al., 1998, 
Richter et al., 1998).  Moreover, functional neuroanatomical studies have shown that 
measures of GU and CO activity capture different aspects of network activity (Jacquin et 
al., 1993).  As noted, signals derived from CO histochemistry are concentrated at sites 
with mitochondrial density, whereas the signals of 2-DG autoradiography predominate at 
axon terminals with high Na+-K+-ATPase activity (Di Rocco et al., 1989).   
 
Overall, functional brain mapping in hMT1 mice demonstrated a shift of 
metabolic demand from the basal ganglia to the cerebellum.  In the basal ganglia, the 
decreased GU noted in the MGP and LGP might be due, in part, to decreased CO activity 
in CPu neurons, which send GABAergic projections to MGP, LGP, and SNR.  In MGP 
and SNR, CO was also reduced.  In agreement with these findings, independent studies in 
human subjects with generalized and focal dystonias have found significantly reduced 
mean GPi firing rates (Starr et al., 2005; Tang et al., 2007).  These changes in CO activity 
in MGP and SNR mirror complicated results in the dystonic hamster (Nobrega et al., 
1998).  Although likely associated, our approach does not allow us to ascribe the hMT1 
metabolic abnormalities in the basal ganglia to the increased nigrostriatal dopaminergic 
turnover in hMT1 mice.  
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Interestingly, hypermetabolism in the cerebellar hemispheres has been reported in 
non-manifesting DYT1 carriers (Eidelberg, 1998; Trost et al., 2002; Carbon et al., 
2004a).  Compatible with these clinical results, we identified hypermetabolism in the 
Purkinje cell layer (PCL) of cerebellum in hMT1 mice.  In our model, increased GU/CO 
activity in the inferior olive, which sends excitatory input to cerebellar Purkinje cells via 
the climbing fiber pathway, might alter the firing properties of Purkinje cells-as has been 
described in the dt rat (LeDoux and Lorden, 2002).  Elevated Purkinje cell firing rates 
would be associated with an enhanced metabolic activity at GABAergic synaptic 
terminals in the cerebellar nuclei; similar results have been identified in the dt rat 
(Ledoux, 2004).  Although it is not possible to specifically attribute the gait abnormalities 
in hMT1 mice to dysfunction of either the basal ganglia or cerebellum, increased 
hindbase width is classically associated with dysfunction of the latter.  Theoretically, this 
cerebellar abnormality could be primary or secondary to dysfunction of the basal ganglia.  
However, in DYT1 carriers, functional imaging suggests the primary dysfunction of the 
basal ganglia leads to compensatory maladaptive neural output from the cerebellum 
(Ghilardi et al., 2003; Carbon et al., 2008b).   
 
The inferior olive may play a central node in communication between the basal 
ganglia-thalamocortical and olivocerebellar circuits (Alexander and Crutcher, 1990; 
Marshall and Lang, 2004).  The inferior olive receives a wide variety of excitatory and 
GABAergic projections (Walberg, 1956, , 1974; Berkley and Hand, 1978; Berkley and 
Worden, 1978; Saint-Cyr and Courville, 1981; Swenson and Castro, 1983). Inferior 
olivary afferents arise from the spinal cord, medulla, pons, midbrain, cerebellar nuclei, 
and cerebral cortex. Projections from the red nucleus, periaqueductal gray, and other 
midbrain nuclei such as the interstitial nucleus of Cajal, nucleus of Bechterew, and 
nucleus of Darkschewitsch enter the central tegmental tract, descend uncrossed, and 
terminate in the inferior olive.  Fibers, which ascend in the spinal cord, reach the inferior 
olive either directly through the spino-olivary tract that courses through the anterior 
funiculus or indirectly via the dorsal column nuclei.  Dysfunction of one or more of these 
afferents might induce hypermetabolism and altered neuronal activity in the IO.  
Alternatively, a defect intrinsic to the IO could be causally associated with 
pathophysiology of DYT1 dystonia because climbing fiber dysfunction is critical to the 
dystonic movement disorders of the dt rat and rats treated with the neurotoxin 3-
acetylpyridine (Sukin et al., 1987; Ledoux, 2004).  
 
With a 2-DG autoradiography protocol similar to our own, striking increases in 
GU were detected in the cerebellar nuclei of the dt rat (Brown and Lorden, 1989).  In the 
dt rat, correlations for GU in regions with known anatomical connections also suggested 
that basal ganglia efferents might be abnormal.  The GU metabolism pattern identified in 
hMT1 transgenic mice show important qualitative similarities to patterns described in dt 
rats.  However, the magnitude of the changes in hMT1 mice was small relative to 
alterations seen in the dt rat-probably due to the fact that the latter model exhibits a 
profound generalized dystonia.  Clearly, the cerebellum contributes to the dystonic 
movement disorder of the dt rat, which is eliminated by cerebellectomy (LeDoux et al., 
1993; LeDoux et al., 1995).   
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Our correlation analysis supports the validity of our findings.  In particular, the 
correlations that we obtained in control mice are similar to values previously reported in 
hamsters and rats (Brown and Lorden, 1989; Richter et al., 1998).  For specific examples, 
mice, rats, and hamsters show positive correlations between the cerebellar nuclei (medial 
and interpositus) and the red nucleus.  In addition, positive correlations between the 
striatum and LGP have been described in all three species of rodents.  These and several 
other correlations in control mice, including positive correlations of rostral caudate-
putamen to MGP, negative correlations of rostral caudate-putamen to subthalamic 
nucleus, and negative correlations of MGP to STh, were disrupted in hMT1 mice.   
 
Reduced GPi output to the thalamus might result in enhanced thalamocortical 
activation.  In similar fashion, reduced SNR output might result in enhanced activity in 
the tectal and tegmental pathways, which receive inhibitory projections from SNR.  
Clearly, DYT1 dystonia is a network disorder of similar topography among manifest and 
non-manifest carriers of the ΔGAG mutation.   
 
 
3.5 CONCLUSIONS 
 
In summary, our study has provided a vigorous analysis of the genetic, motoric, 
morphological, neurochemical, and brain metabolic features of the hMT1 transgenic 
mouse model of DYT1 dystonia.  The hMT1 model exhibits distinct motor, 
neurochemical, and brain metabolical phenotypes that result from the cellular burden of 
mutant torsinA.  The increased DA turnover identified in hMT1 mice is noteworthy 
because tetrabenazine, a dopamine-depleting drug, has been used successfully in patients 
with generalized dystonia (Jankovic and Orman, 1988).  Furthermore, mutant torsinA 
appears to interfere with the dopamine and vesicular monoamine transporters (Torres et 
al., 2004; Cao et al., 2005; Misbahuddin et al., 2005).  Thus, the hMT1 mouse might be 
used to study the systems and cellular biology of torsinA and to evaluate potential 
therapeutics for DYT1 dystonia.  
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CHAPTER 4. SUMMARY AND DISCUSSION 
 
 
4.1 SUMMARY 
 
In the research presented in the dissertation, the systems biology of torsinA was 
examined with two approaches.  First, perturbation models were used to examine the 
systems biology of torsinA.  Transient forebrain ischemia was used as a CNS 
perturbation and sciatic nerve transection as a PNS perturbation.  The temporal and 
spatial responses of torsinA transcript and protein expression in neural tissues were 
evaluated with QRT-PCR, in situ hybridization, and immunohistochemistry.   Up-
regulation of torsinA expression in neural tissues was found after central and peripheral 
insults.  The initial up-regulation of torsinA transcript after ischemia was localized to the 
major neuronal populations that expressed high levels of torsinA even in the control 
tissues.  However, the delayed component of torsinA up-regulation included prominent 
expression in reactive astrocytes in regions of hippocampus (e.g., CA1) known to 
undergo neuron loss and synaptic reorganization after ischemia.  The up-regulation of 
torsinA in DRG showed similar temporal and spatial patterns to the CNS.  Up-regulation 
of torsinA was detected in ganglion cells and satellite cells in ipsilateral DRG; however, 
torsinA was preferentially concentrated in satellite cells in the contralateral DRG.  Our 
perturbation models have provided the first descriptions of torsinA expression in reactive 
glial elements.  Overall, our findings suggest that torsinA participates in the response of 
neural tissue to central and peripheral insults.  Moreover, the sustained up-regulation of 
torsinA in interneurons and reactive astrocytes in the regions with significant neuron loss 
and putative synaptic reorganization indicates that torsinA might contribute to the 
remodeling of neuronal circuitry.  In addition, the striking induction of torsinA in 
astrocytes and satellite cells points to the potential involvement of glial elements in the 
pathobiology of DYT1 dystonia. 
 
DYT1 transgenic mouse models were used to examine the systems biology of 
torsinA.  We performed an analysis of the motor behavioral, morphological, 
neurochemical, and brain metabolical features of the hMT1 transgenic mouse model of 
DYT1 dystonia.  The hMT1 model exhibits distinct motor, neurochemical, and 
metabolical phenotypes that result from the cellular burden of mutant torsinA.  Compared 
to WT littermates, hMT1 mice showed prolonged traversal times on square and round 
raised-beam tasks, more slips on the round raised-beam task, and increased hind-base 
widths in foot-print analysis.  No distinguishing cytoplasmic torsinA-positive inclusion 
bodies or nuclear envelop abnormalities were noted in hMT1 mice.  However, significant 
increases of striatal DOPAC, HVA, and DA turnover (DOPAC/DA and HVA/DA) were 
found in hMT1 mice.  Brain metabolic abnormalities include a shift of metabolic demand 
from structures of basal ganglia to olivocerebellar pathways in hMT1 mice compared to 
controls.  Our findings in DYT1 transgenic mice are compatible with previous 
postmortem neurochemical studies of human DYT1 dystonia.  Increased striatal DA 
turnover in hMT1 mice suggests that the nigrostriatal pathway might be a site of 
functional neuropathology in DYT1 dystonia.  Increased activity in the direct and indirect 
pathways, and the relatively attenuated metabolic demand in basal ganglia output regions, 
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might be the primary consequence of a functional defect in the dopaminergic nigrostriatal 
system in DYT1 mutation carriers.   The increased metabolic demands in olivocerebellar 
pathways (inferior olive, Purkinje cells, cerebellar nuclei) might be a compensatory 
network response to increases thalamocortical activity.  Alternatively, hypermetabolism 
in olivocerebellar pathways might be largely independent of basal ganglia-
thalamocortical dysfunction, in which case interactions between these two sensorimotor 
networks contribute to the generation of a dystonic phenotype.  In aggregate, our data 
provide evidence that the hMT1 mouse might be used to study the systems and cellular 
biology of torsinA, and to evaluate potential therapeutics for DYT1 dystonia. 
 
 
4.2 DISCUSSION 
 
Our findings of torsinA up-regulation after central and peripheral insults are 
compatible with studies of developmental expression because up-regulation was also 
noted during the period of neurogenesis and synaptic reorganization after forebrain 
ischemia.  In the hippocampus, an increased level of torsinA-IR was prominent in the 
subgranular proliferative zone, which is the site of neuroblast proliferation after ischemia.  
Increased torsinA-IR was also localized to cell populations in the SR, SO, and SLM in 
regions of hippocampus (e.g., CA1) known to undergo neuron loss and synaptic 
reorganization.  Many of the cells in the CA1 region that showed overt up-regulation of 
torsinA-IR were found to be GFAP-IR reactive astrocytes, somatostatin-IR interneurons, 
and parvalbumin-IR interneurons.  Glia may facilitate synaptic formation and synaptic 
neurotransmitter release, and direct neuronal migration and neurite extension (Powell et 
al., 1997; Araque et al., 1999; Grosche et al., 1999; Ventura and Harris, 1999; Riquelme 
et al., 2002; Liu et al., 2004; Sobkowicz et al., 2006; Bystron et al., 2008).  The up-
regulation of torsinA in reactive astrocytes might facilitate neuronal-network 
reorganization by guidance of neuronal migration, neurite extension, or enwrapping many 
pre- and post-synaptic terminals.  Alternatively, torsinA might contribute to the 
morphological and topological changes that reactive astrocytes must undergo in order to 
facilitate synaptogenesis and network reorganization (Lepekhin et al., 2001; Witcher et 
al., 2007).  The surviving interneurons in the CA1 region also undergo significant 
morphological changes, and might serve as substitute targets for Schaffer collateral and 
other excitatory synaptic input after hippocampal ischemia (Arabadzisz and Freund, 
1999).  Accordingly, it is rational to postulate that torsinA might participate in structural 
changes and/or transport of cell surface receptors in these hippocampal interneurons.   
 
Via indirect cytoskeletal interactions, torsinA might also participate in the 
formation of neurotransmitter vesicles and vesicular recycling (Augood et al., 2002; 
Asanuma et al., 2005; Shashidharan et al., 2005; Dang et al., 2005; 2006; Balcioglu et al., 
2007; Grundmann et al., 2007).  In support of this concent, Augood and colleagues 
(2002) found a significantly increased DOPAC/ DA ratio, along with a trend toward 
reduction in D1 and D2 receptor binding in the striatum in postmortem DYT1 dystonia 
brains.  Moreover, a variety of neurochemical alterations have been described in DYT1 
knock-in, knock-down, and transgenic mice (Shashidharan et al., 2005; Dang et al., 2005; 
2006; Balcioglu et al., 2007; Grundmann et al., 2007).  Finally, Granata and co-workers 
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(2008) found that synaptic vesicle recycling is regulated by torsinA expression.  
Endogenous torsinA plays an important role to regulate the rate of synaptic vesicle 
turnover.  Importantly, overexpression of mutant torsinA significantly impaired the 
process of vesicular endocytosis.   
 
In line with previous human work and the recent publication by Granata et al. 
(2008), our studies revealed significant increases of striatal DOPAC, HVA, and DA 
turnover (DOPAC/DA and HVA/DA) in hMT1 mice.  Increases in the DOPAC/DA and 
HVA/DA ratios could be the manifestation of increased DA release, decreased DA 
uptake due to abnormal functioning of the dopamine and/or vesicular monoamine 
transporters or increased monoamine oxidase activity.  In another study with hMT1 mice, 
normal basal levels of striatal extracellular DA and decreased amphetamine-induced DA 
release were identified (Balcioglu et al., 2007).  Taken together, these findings suggest 
that mutant torsinA disrupts nigrostriatal dopaminergic neurotransmission by interfering 
with the normal biology of dopamine-containing vesicles and dopamine transporters at 
the axon terminal.   
 
In conclusion, the body of work included in this dissertation provides important 
new insights into the systems biology of torsinA.  The burden of mutant torsinA on 
motor, neurochemical, morphological, and metabolic phenotypes was characterized in 
mice and the role of normal torsinA in the central and peripheral nervous systems was 
explored in perturbation models.  Although our findings do not provide definitive roles 
for wild-type and mutant torsinA in normal neural function and the pathobiology of 
DTY1 dystonia, they do point out clear avenues for future study.  In particular, the 
neurochemical and metabolic abnormalities in hMT1 mice suggest that the metabolic 
topography of the DYT1 carrier state might be due to a primary defect in nigrostriatal 
neurotransmission.  Furthermore, the appearance of dystonia might be due to 
compensatory and maladaptive changes by the olivocerebellar network.  Perturbation 
models suggest that torsinA participates in reparative responses of the nervous system. 
Thus, DYT1 dystonia appears to be a network disorder of reduced penetrance, which 
could require an environmental perturbation to become clinically manifest.  Given this 
conceptualization, it may be  useful to determine if perturbations such as transient 
cerebral ischemia, hyperthermia or repetitive sensorimotor tasks can precipitate the 
appearance of a dystonic phenotype in hMT1 mice.
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